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Abstract  1 
Although the use of clotting factor concentrates is the mainstay of haemophilia care, 2 
the development of inhibitors complicates disease management. Perioperative 3 
management of patients with inhibitors is therefore a challenge. A systematic 4 
literature review was performed to identify literature reporting on the perioperative 5 
monitoring and management of haemophilia. MEDLINE, Embase and Cochrane 6 
databases were searched from database inception to 26 March 2018. Recent 7 
congress proceedings were also searched. Titles and abstracts, then full texts, were 8 
screened for relevance by two reviewers. Quality of included studies was assessed 9 
using the Critical Appraisal Skills Programme checklist. Of the 2,033 individual entries 10 
identified, 86 articles met the inclusion criteria. The identified studies were screened 11 
again to find papers reporting perioperative laboratory monitoring in patients with 12 
congenital haemophilia A or B, resulting in 24 articles undergoing data extraction. 13 
Routine perioperative assay monitoring practices were the most commonly reported 14 
(n=20/24); thrombin generation assay (TGA) was the least commonly reported 15 
(n=2/24). Other monitoring practices described were factor VII and factor VIII 16 
coagulation activity (FVII:C, FVIII:C) (n=8/24, n=5/24, respectively), and 17 
thromboelastography (TEG) or rotational thromboelastometry (ROTEM) assessments 18 
(n=3/24). The impact of monitoring on treatment decisions was, however, rarely 19 
reported. In conclusion, many methods of perioperative monitoring of haemophilia 20 
patients with inhibitors have been identified in this review, yet there is a lack of 21 
reporting in larger scale cohort studies. More detailed reporting on the impact of 22 
monitoring outcomes on treatment decisions is also needed to share best practice, 23 
particularly as new therapeutic agents emerge. 24 
Key words: Haemophilia; Surgery; Inhibitors; Laboratory Monitoring; Systematic 25 
Literature Review 26 
 27 
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INTRODUCTION 1 
Haemophilia is a rare disease caused by a deficiency of coagulation factor VIII 2 
(FVIII) (haemophilia A, HA) or factor IX (FIX) (haemophilia B, HB) and leaves 3 
patients more prone to excessive bleeding.[1] The standard of care for severe 4 
haemophilia (factor activity <1 IU/dl), and some patients with moderate haemophilia 5 
(factor activity 1-5 IU/dl), is to prevent or minimise bleeding episodes using infusions 6 
of the missing factor concentrate (prophylaxis). Breakthrough bleeds may still occur 7 
requiring additional on-demand treatment. Treatment protocols, intensity of 8 
prophylaxis or choice to remain on-demand alone must be tailored to individual 9 
needs together with consideration of the local health economics.[1]  10 
In response to regular treatment, a subgroup of haemophilia patients of all severities 11 
can produce immunoglobulin G (IgG) DQWLERGLHVWHUPHGµLQKLELWRUV¶, which work to 12 
neutralise clotting factors.[2, 3] Inhibitors complicate prophylaxis and on-demand 13 
management by reducing or fully neutralising the efficacy of infused factor 14 
concentrates, depending on the detected inhibitor titre.[1, 4] 15 
Persistent inhibitors are a concern for haemophilia patients, particularly if undergoing 16 
surgical procedures.[5] Permanent tolerance induction in severe haemophilia 17 
(immune tolerance induction, ITI) is the preferable strategy to minimise future 18 
bleeding and/or management risks of surgery in the presence of an inhibitor.[6, 7] 19 
Tolerising practices may also include the use of anti-CD20 monoclonal antibody, 20 
immunoadsorption and plasmapheresis for additional short-term benefit.[5] 21 
Strategies for re-achieving tolerance in non-severe HA are less well defined.[8] 22 
Knowledge of previous and/or current inhibitor status prior to surgery is crucial, 23 
either as repeat laboratory assessment ahead of surgery if time allows (severe 24 
haemophilia), reference to laboratory screening since the most recent FVIII 25 
concentrate exposure (non-severe HA), or attention to in vivo recovery and 26 
perioperative efficacy of infused concentrate (all severities) during the peri- and 27 
post-surgical course.[6, 9] 28 
The monitoring and management of haemophilia patients with inhibitors undergoing 29 
surgical procedures is a particular challenge, and is the focus of this review. 30 
MATERIALS AND METHODS 31 
Search Strategy for Identification of Studies 32 
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A systematic literature review was performed in accordance with a pre-specified 1 
search protocol designed to identify literature reporting on the perioperative 2 
monitoring and management of haemophilia patients with inhibitors. The review 3 
process involved searching electronic databases, and hand-searching of key 4 
haemophilia/haematology conference proceedings from the last two years and 5 
reference lists of any relevant systematic reviews identified during the searches. 6 
All electronic databases were searched on 26 March 2018. The databases searched 7 
to identify relevant published literature were: MEDLINE, MEDLINE In-Process, 8 
MEDLINE Daily and MEDLINE Epub Ahead of Print (1946 to present); Embase (1974 9 
to 23 March 2018); The Cochrane Database of Systematic Reviews (CDSR): Issue 3 10 
of 12, March 2018; The Database of Abstracts of Reviews of Effects (DARE): Issue 2 11 
of 4, April 2015; The Cochrane Central Register of Controlled Trials (CENTRAL): 12 
Issue 2 of 12, February 2018. 13 
In addition to the electronic database searches, hand-searches were performed to 14 
generate further evidence from a variety of sources. The bibliographies of published 15 
systematic reviews identified through the electronic database searches were hand-16 
searched to identify any additional relevant studies for inclusion in the review. The 17 
proceedings of relevant haemophilia and haematology congresses that had taken 18 
place within approximately two and a half years prior to December 2017 were also 19 
hand-searched, including: American Society of Hematology Annual Meeting (2015, 20 
2016, 2017); British Society for Haematology Annual Scientific Meeting (2016, 2017); 21 
European Association for Haemophilia and Allied Disorders Annual Congress (2016, 22 
2017); Haemophilia and Thrombosis Research Society Scientific Symposium (2015, 23 
2017); European Hematology Association (EHA) Congress (2016, 2017); 24 
International Society for Thrombosis and Haemostasis Congress (2016, 2017); World 25 
Federation of Hemophilia (WFH) World Congress (2016). The websites and abstract 26 
books of these congresses were searched, if available, using terms based on the 27 
complete list of electronic database search terms.  28 
Full details of the search strategies for the electronic database searches and the 29 
congress searches are presented in Supplementary Table 1±3. 30 
Study Selection 31 
All articles retrieved through the electronic database searches and hand-searches 32 
were screened by two independent reviewers and included based on their alignment 33 
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with the predefined eligibility criteria (Supplementary Table 4). The strategy was 1 
specifically designed to capture studies reporting on the monitoring and/or 2 
management of haemophilia patients with inhibitors undergoing surgery. All articles 3 
were initially screened based on their abstracts only. Following the abstract review 4 
stage, the full texts of remaining articles were then screened for relevance to 5 
produce the final list of included studies. For pragmatic reasons, additional study 6 
design eligibility criteria were applied during the screening of full texts to ensure that 7 
only interventional and observational studies were included in the final list. Study 8 
designs were determined by their description as reported by authors in the papers. 9 
In cases where the study design was not explicitly stated, the reviewers defined 10 
observational studies as those that examined and analysed the data of a patient 11 
cohort as a group, compared to an analysis of individual patient data only in case 12 
series. Studies that described patients being assigned to a specific treatment group 13 
were categorised as interventional. A full list of papers excluded, and the reasons for 14 
their exclusion, at the full text screening stages of the review is shown in 15 
Supplementary Table 5. In addition, a list of the case studies identified during the 16 
review and excluded based on study design prior to full text screening is available in 17 
Supplementary Table 6. 18 
Data Extraction and Analysis 19 
Following application of the eligibility criteria, there was still a large number of 20 
included studies. Therefore, the list was screened an additional time by one 21 
reviewer, and checked by a second reviewer, to identify the studies that reported 22 
perioperative laboratory monitoring in patients with congenital HA or HB. In cases of 23 
studies reporting on both congenital and acquired haemophilia patients, only 24 
information on congenital patients was extracted. Data were extracted from each 25 
article by a single individual, and reviewed by a second. 26 
Since included studies are of different designs, their quality was assessed using the 27 
Critical Appraisal Skills Programme (CASP) checklist most appropriate for the study 28 
design (e.g. case control study, cohort study, randomised controlled trial). 29 
RESULTS   30 
Search Results 31 
The literature search retrieved 1,481 abstracts from electronic databases, 502 32 
abstracts from conference proceedings and 50 articles from hand searches of 33 
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existing review bibliographies. Following application of the eligibility criteria to the 1 
identified abstracts and, subsequently, full text articles (Figure 1), a final list of 86 2 
relevant articles was identified (Table 1).  3 
In the interest of focusing the review more specifically, the 86 full text articles were 4 
screened once more to identify the studies reporting perioperative laboratory 5 
monitoring in patients with congenital HA or HB and inhibitors. This resulted in a final 6 
list of 24 articles that underwent full data extraction (Table 2). 7 
Quality Assessment 8 
Quality assessments were carried out for the interventional and observational studies 9 
that underwent data extraction (Supplementary Table 7±8). Overall, the issues 10 
addressed by the interventional studies were clearly focused and all patients were 11 
properly accounted for. The most substantial limitation of the interventional studies 12 
was a lack of blinding (8/9 studies), which may have led to bias in the ascertainment 13 
and reporting of outcomes. For the observational studies, follow-up was almost 14 
always complete (14/15) but due to a lack of reporting, many of the quality 15 
assessment questions had to be marked as not applicable. 16 
Perioperative Monitoring 17 
Overall, 40% (34/86) of articles identified through the review mentioned how 18 
patients were monitored; of these, nearly three quarters (24) of the articles 19 
mentioned the use of laboratory monitoring in patients with inhibitors complicating 20 
congenital HA or HB, either in the methods section or when describing the outcomes 21 
of the study (Table 1). However, even in studies which mentioned laboratory 22 
monitoring, the use and impact of specific monitoring protocols on treatment 23 
decisions was often not well described. Instead, it was common for the details of 24 
perioperative monitoring to be provided for information only, or to report the 25 
haemostatic efficacy of the treatment. 26 
Routine laboratory monitoring 27 
Amongst the studies reporting perioperative laboratory monitoring practices, routine 28 
laboratory monitoring practices, such as platelet count, prothrombin time (PT), 29 
activated partial thromboplastin time (APTT), fibrinogen levels, D-dimer levels and 30 
antithrombin (ATIII) were the most commonly reported. This monitoring information 31 
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was frequently provided to demonstrate efficacy, or lack thereof, and determine 1 
safety, of the haemostatic agent, particularly in the context of interventional 2 
studies.[10, 11] In the majority of studies it was unclear whether the outcomes of 3 
laboratory tests were available to the care team within the timeframe necessary to 4 
influence treatment decisions (Table 3).[12, 13] 5 
When the influence of monitoring on clinical decisions was discussed, this was mainly 6 
in the context of individual patient cases, such as reduction in activated prothrombin 7 
complex concentrate (aPCC) treatment following elevation in D-dimer levels,[14] as 8 
opposed to providing insight into how laboratory monitoring influenced treatment 9 
decisions and outcomes on a cohort-wide level. In other cases, laboratory tests were 10 
only utilised in patients who experienced an adverse event.[15] 11 
Overall, very limited information was found in the identified studies to indicate the 12 
influence of perioperative monitoring results on clinical decisions. 13 
Factor VII 14 
A total of 8 of the 17 extracted studies describing treatment with recombinant factor 15 
VIIa (rFVIIa), administered continually (CI) or using bolus doses, described the 16 
monitoring of factor VII coagulation activity (FVII:C) (Table 4). Two studies 17 
published by the same centre described monitoring FVIIa levels using a one-stage 18 
coagulation assay suggesting that coagulation activity as opposed to protein levels 19 
was assessed. The studies from this centre also report that the specific FVIIa assay 20 
(StaclotTM, Diagnostica Stago) was not found to be practical or reliable.[16, 17] 21 
Even where FVII:C monitoring is mentioned, FVII:C was rarely used to make dosing 22 
decisions. In one study investigating continuous infusion of rFVIIa, observed 23 
bleeding was used to deduce that the target FVII:C of 10 IU/dl was insufficient.[18] 24 
Two other studies noted that in patients with ineffective haemostatic efficacy, FVII:C 25 
often exceeded the target 30 IU/ml.[10, 19] 26 
When comparing CI to bolus administration, one study found that FVII:C levels were 27 
consistently higher in patients undergoing CI; however, the difference was not 28 
statistically significant, and there was no difference in haemostatic efficacy between 29 
groups (75% vs. 73%, respectively).[19] 30 
Thromboelastography/Rotational thromboelastography analysis 31 
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Thromboelastography (TEG) or rotational thromboelastography (ROTEM) coagulation 1 
assessments were used in three of the more recent studies assessing a variety of 2 
agents (including rFVIIa, aPCC, and FVIII) (Table 5). In one study, ROTEM analysis 3 
on in vitro samples was used to identify the minimum necessary dose of activated 4 
coagulation products and most suitable treatment (rFVIIa vs. aPCC) for perioperative 5 
haemostatic control in patients with inhibitors.[20] This study found that 6 
preoperative in vitro ROTEM analysis more accurately predicted the impact of 7 
treatment with rFVIIa than with aPCC.[20] The other studies used ROTEM 8 
intraoperatively to demonstrate haemostatic efficacy, but did not report how the 9 
outcomes impacted clinical treatment decisions.[21, 22]  10 
Factor VIII:C 11 
Four studies were found to have analysed human FVIII:C, while one analysed 12 
porcine FVIII:C (Table 6).[13, 21-24] The use of FVIII:C to identify cases of 13 
µUHVLVWDQFH¶WRSRUFLQH)9,,,FRQFHQWUDWHZas discussed in an early study,[13] 14 
however, only one recent study mentioned how FVIII:C monitoring influenced 15 
treatment decisions.[24] This retrospective observational study involved routine 16 
monitRULQJRI)9,,,&DQGZKHQRQHSDWLHQW¶V)9,,,&OHYHOVGHFOLQHGDIWHUDWRWDO17 
knee replacement, their treatment was switched from cryoprecipitate to plasma-18 
derived FVIII (pdFVIII), leading to a good haemostatic outcome.[24] 19 
Thrombin generation 20 
Only two articles described monitoring using a thrombin generation assay (TGA) 21 
(Table 7).[22, 25] In one of these studies, TGA parameters were used to assess 22 
haemostatic efficacy, with no indication of how the results impacted care 23 
decisions.[22] The other, a 2016 study involving 10 inhibitor patients undergoing 24 
orthopaedic surgery, investigated the association between TGA and clinical bleeding 25 
events, finding that there was no difference in the TGA values between patients who 26 
did and did not experience bleeding complications.[25] 27 
DISCUSSION 28 
Whilst this review uncovered evidence on the methods of monitoring and 29 
management used in haemophilia patients undergoing surgery, there was very little 30 
information to indicate how the outcomes of laboratory monitoring practices were 31 
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used to influence treatment decisions. In papers where the impact of monitoring was 1 
mentioned, this tended to be described on an individual patient basis. Therefore, it is 2 
difficult to use the available evidence to understand to what extent laboratory 3 
monitoring is used in clinical practice and how it could be utilised to improve patient 4 
care. 5 
Another barrier to understanding the impact of perioperative monitoring in 6 
haemophilia patients is the lack of a generalisable assay for aPCC and rFVIIa. 7 
Monitoring of patients undergoing treatment with these agents is currently 8 
conducted according to local protocols, instead of a global standard, with centres 9 
forced to evaluate treatment efficacy through clinical, rather than laboratory, 10 
assessments. 11 
In addition, while some evidence related to monitoring and management with 12 
traditional treatments, such as rFVIIa, aPCC and FVIII was found, the review did not 13 
identify published literature reporting on such practices in patients treated with 14 
emerging therapeutics, such as emicizumab, concizumab and fitusiran. There are 15 
currently only anecdotal data about surgical haemostasis planning in patients with 16 
these agents on board.[26, 27] In such scenarios, monitoring for all these agents will 17 
be complex, both in terms of consideration of appropriate laboratory assays, 18 
together with interpreting results in the context of global haemostatic potential. 19 
Emicizumab, a recombinant, humanised, bispecific monoclonal antibody recently 20 
approved for treatment of HA with inhibitors by the Food and Drug Administration 21 
(FDA), works by acting similarly to activated factor VIII in bridging activated factor 22 
IX and factor X to trigger the coagulation cascade.[28] As emicizumab affects 23 
intrinsic pathway clotting-based laboratory tests, including activated clotting time 24 
(ACT) and all assays based on APTT, intrinsic pathway clotting-based laboratory test 25 
results should not be used to monitor emicizumab activity, determine dosing for 26 
factor replacement or anti-coagulation, or measure FVIII inhibitor titres in patients 27 
receiving this treatment.[29] A recent case study describing the use of rescue aPCC 28 
treatment to provide additional haemostatic control during a spontaneous bleeding 29 
event in a patient receiving prophylactic emicizumab used TGA to determine the 30 
optimal aPCC dosage to maintain haemostatic efficacy while limiting the risk of 31 
thrombotic complications.[30] While this review identified an interventional study 32 
reporting the use of emicizumab in haemophilia patients with inhibitors undergoing 33 
surgery, no information on perioperative laboratory monitoring was provided.[27] 34 
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Concizumab, a humanized monoclonal antibody against tissue factor pathway 1 
inhibitor, is under investigation for the prophylactic treatment of HA and HB patients 2 
with inhibitors in a phase II trial due to complete in 2019 (NCT03196284).[31] 3 
Previous studies have used TGA to demonstrate concizumab activity, suggesting that 4 
this may be a potential method of evaluating efficacy in clinical practice.[32] Lastly, 5 
fitusiran, an investigational RNA interference therapy, works by targeting ATIII 6 
messenger RNA to suppress ATIII production.[33] One interventional study 7 
examining fitusiran treatment in haemophilia patients undergoing surgery was 8 
identified in this review, but no details on perioperative laboratory monitoring were 9 
reported.[34] As these emerging therapies enter the market it will be important to 10 
establish an understanding of the standard of care used to monitor patients receiving 11 
these treatments. 12 
While data on these emerging therapies are currently limited it is difficult to predict 13 
response to treatment during surgery, as well as expectations from monitoring. 14 
Efforts have been made to standardise TGA, but these developments are rarely 15 
shared outside of research settings. More information is therefore needed to 16 
understand their use in patients with inhibitors undergoing surgery in clinical 17 
practice. As the availability of data on suitable assays remains limited, the United 18 
.LQJGRP+DHPRSKLOLD&HQWUHV'RFWRUV¶2UJDQLVDWLRQhas recommended that non-19 
urgent major surgery in haemophilia patients with inhibitors receiving novel 20 
prophylaxis agents is delayed, until more specific methods of monitoring these 21 
patients can be found or treatment algorithms and risks are better understood.[35] 22 
For pragmatic reasons, the scope of the review was limited to include only 23 
interventional and observational studies. The results of this review indicate that the 24 
currently available higher quality evidence base provides little insight into the 25 
standard of care for the use of laboratory monitoring in the management of 26 
haemophilia patients with inhibitors undergoing surgery. This topic has also been 27 
addressed in case studies and series, including a case series reported by Dargaud et 28 
al. in 2010.[36] This paper investigated the use of TGA in monitoring efficacy of 29 
agents in surgical procedures for six patients and showed that TGA results correlated 30 
with clinical bleeding risk and endogenous thrombin potential can be used to monitor 31 
agent efficacy in their hands.[36] These results were not supported by a later, larger 32 
scale study involving 10 inhibitor patients undergoing surgery identified by our 33 
review however, as no significant differences in TGA parameters between 34 
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haemophilia patients with inhibitors who did and did not experience bleeding 1 
complications following surgery were found.[25] Whilst case studies and series can 2 
provide valuable insight, they are considered to be a source of lower quality evidence 3 
due to their risk of bias and potential lack of generalisability to a wider patient 4 
population. The results of this review, therefore, highlight the need to report higher 5 
quality evidence on monitoring and managing surgical haemophilia patients with 6 
inhibitors to establish a standard of care in this area.  7 
CONCLUSION 8 
In conclusion, this systematic literature review demonstrated that there are multiple 9 
methods of laboratory monitoring used in haemophilia patients with inhibitors 10 
undergoing surgery, although these are largely reported in the context of clinical 11 
trials looking to evaluate unforeseen complications of candidate haemostatic agents. 12 
Currently no generalisable assays exist for examining treatment efficacy against high 13 
titre inhibitors, and instead clinicians are forced to rely on empirical dosing and 14 
consensus guidance. With the introduction of novel agents, this landscape may be 15 
complicated further. Where data on monitoring of inhibitor treatment exist, there is 16 
little information from higher quality evidence sources to indicate how the outcomes 17 
of such practices are used to inform treatment decisions. There is a need to develop 18 
more robust evidence in this area to establish a standard of care for perioperatively 19 
monitoring haemophilia patients with inhibitors who are treated with current and 20 
emerging haemostatic therapies. 21 
ACKNOWLEDGEMENTS 22 
This review was funded by Roche Products Ltd and Chugai Pharma UK Ltd. The 23 
authors acknowledge Costello Medical Consulting, UK, for writing and editorial 24 
assistance (funded by Roche Products Ltd and Chugai Pharma UK Ltd).  25 
$OODXWKRUVPHHWWKH,QWHUQDWLRQDO&RPPLWWHHRI0HGLFDO-RXUQDO(GLWRUV¶FULWHULDIRU26 
authorship and have made substantial contributions to the conception, design, 27 
execution or analysis and interpretation of the data: 28 
Study conception/design and acquisition of data: DPH, CRMH, RL, GT, BDM, MM; 29 
analysis/interpretation of data: DPH, CRMH, RL, GT, BDM, MM; drafting of the 30 
publication, or revising it critically for important intellectual content: DPH, CRMH, RL, 31 
GT, BDM, MM; final approval of the publication: DPH, CRMH, RL, GT, BDM, MM.  32 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
12 
 
CONFLICTS OF INTEREST/DISCLOSURES 1 
DPH has received research support from Octapharma, Bayer and Shire, speaker 2 
and/or consultancy honoraria from Pfizer, Shire, Sobi, Biomarin, Uniqure, Roche, 3 
Octapharma, Novo Nordisk and Biotest; CRMH has attended advisory boards 4 
organised by Roche, received research support from Novo Nordisk, Pfizer, Shire, 5 
Bayer and Sobi, and acted as speaker in sponsored symposia for Pfizer, Shire, Bayer, 6 
Sobi and Biotest; RL has received speaker fees from Octapharma, BPL and Bayer, 7 
consultancy fees from Bayer, Octapharma, Novo Nordisk, Shire and Grifols, has 8 
attended an advisory board organised by Roche, and was an investigator for the 9 
HAVEN 2 study; GT is an employee of Roche Products Ltd.; BDM is an employee of 10 
Costello Medical; MM has provided consultancy to CSL Behring and Novo Nordisk and 11 
attended advisory boards organised by Shire and Bioverativ.  12 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
13 
 
REFERENCES 1 
1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the 2 
management of hemophilia. Haemophilia. 2013 Jan;19(1):e1-47. 3 
2. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation 4 
and risk of inhibitor development in nonsevere hemophilia A. Blood. 5 
2013;122(11):1954-62. 6 
3. Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor 7 
VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine. 8 
2016;374(21):2054-64. 9 
4. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. 10 
Haematologica. 2000 Oct;85(10 Suppl):15-20. 11 
5. Teitel JM, Carcao M, Lillicrap D, et al. Orthopaedic surgery in haemophilia 12 
patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative 13 
care. Haemophilia. 2009;15(1):227-39. 14 
6. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII 15 
and IX inhibitors in congenital haemophilia: (4th edition). British Journal of 16 
Haematology. 2013;160(2):153-70. 17 
7. Hay CRM, DiMichele DM. The principal results of the International Immune 18 
Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335-44. 19 
8. van Velzen AS, Eckhardt CL, Hart DP, et al. Inhibitors in nonsevere 20 
haemophilia A: outcome and eradication strategies. Thrombosis and haemostasis. 21 
2015 // 22 
22.11.2017;114(07):46-55. 23 
9. Batty P, Austin SK, Khair K, et al. Treatment burden, haemostatic strategies 24 
and real world inhibitor screening practice in nonʘsevere haemophilia A. British 25 
Journal of Haematology. 2017;176(5):796-804. 26 
10. Ludlam CA, Smith MP, Morfini M, et al. A prospective study of recombinant 27 
activated factor VII administered by continuous infusion to inhibitor patients 28 
undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy 29 
evaluation. British Journal of Haematology. 2003 01 Mar;120(5):808-13. 30 
11. Pruthi R, Mathew P, Valentino L, Seremetis S. An open-label, randomized, 31 
parallel, multi-center trial comparing the safety and efficacy of rFVIIa when 32 
administered as I.V. bolus or I.V. continuous infusion to hemophilia patients with 33 
Inhibitors during and after surgery. Blood, 2004:79b-80b. 34 
12. Balkan C, Karapinar D, Aydogdu S, et al. Surgery in patients with haemophilia 35 
and high responding inhibitors: Izmir experience. Haemophilia. 2010 Nov;16(6):902-36 
9. 37 
13. Gatti L, Mannucci PM. Use of porcine factor VIII in the management of 38 
seventeen patients with factor VIII antibodies. Thrombosis and haemostasis. 1984 39 
Jul 29;51(3):379-84. 40 
14. Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY. Surgical interventions in a 41 
cohort of patients with haemophilia A and inhibitors: An experiential retrospective 42 
chart review. Haemophilia. 2007 September;13(5):508-17. 43 
15. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII 44 
or IX or factor VII deficiency. Haemophilia. 1999;5(4):253-9. 45 
16. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Peerlinck K. 46 
Continuous infusion of recombinant factor VIIa in patients with haemophilia and 47 
inhibitors. Experience in The Netherlands and Belgium. The Netherlands journal of 48 
medicine. 1998 Dec;53(6):249-55. 49 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
14 
 
17. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al. Efficacy of 1 
recombinant factor VIIa administered by continuous infusion to haemophilia patients 2 
with inhibitors. Haemophilia. 2002 Sep;8(5):649-56. 3 
18. Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII 4 
inhibitor patients using continuous infusion of recombinant activated factor VII: 5 
plasma factor VII activity of 10 IU/ml is associated with an increased incidence of 6 
bleeding. Thrombosis and haemostasis. 2001 Oct;86(4):949-53. 7 
19. Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of 8 
bolus and continuous infusion of recombinant factor VIIa are comparable in 9 
haemophilia patients with inhibitors undergoing major surgery. Results from an 10 
open-label, randomized, multicenter trial. Thrombosis and haemostasis. 2007 11 
Oct;98(4):726-32. 12 
20. Furukawa S, Nogami K, Ogiwara K, et al. Systematic monitoring of hemostatic 13 
management in hemophilia A patients with inhibitor in the perioperative period using 14 
rotational thromboelastometry. Journal of Thrombosis and Haemostasis. 2015 01 15 
Jul;13(7):1279-84. 16 
21. Serban M, Poenaru D, Patrascu J, et al. Risks and challenges of orthopaedic 17 
invasive interventions in haemophilia in a low-resource country. A single-center 18 
experience. Hamostaseologie. 2014;34 Suppl 1:S30-5. 19 
22. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC 20 
(FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in 21 
patients with acquired haemophilia A--a two-centre experience. Haemophilia. 2012 22 
Jul;18(4):544-9. 23 
23. Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AH. Management of 24 
haemophilic patients with inhibitors in major orthopaedic surgery by 25 
immunadsorption, substitution of factor VIII and recombinant factor VIIa 26 
(NovoSeven): a single centre experience. Haemophilia. 2004 Nov;10(6):705-12. 27 
24. Danielson H, Lassila R, Ylinen P, Yrjonen T. Total joint replacement in 28 
inhibitor-positive haemophilia: Long-term outcome analysis in fifteen patients. World 29 
j. 2017 Oct 18;8(10):777-84. 30 
25. Mancuso ME, Chantarangkul V, Clerici M, et al. Low thrombin generation 31 
during major orthopaedic surgery fails to predict the bleeding risk in inhibitor 32 
patients treated with bypassing agents. Haemophilia. 2016 Jul;22(4):e292-300. 33 
26. Santagostino E, Mancuso ME, Novembrino C, et al. Management of Joint 34 
Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis. Blood. 35 
2017;130(Suppl 1):2360-. 36 
27. Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two 37 
multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia a 38 
with inhibitors (HAVEN 1 and HAVEN 2). Blood Conference: 59th Annual Meeting of 39 
the American Society of Hematology, ASH. 2017;130(Supplement 1). 40 
28. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in 41 
Hemophilia A with Inhibitors. The New England journal of medicine. 2017 Aug 42 
31;377(9):809-18. 43 
29. Genentech. HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use. 44 
FULL PRESCRIBING INFORMATION. 45 
https://www.gene.com/download/pdf/hemlibra_prescribing.pdf; 2017. 46 
30. Dargaud Y, Lienhart A, Janbain M, et al. Use of thrombin generation assay to 47 
personalize treatment of breakthrough bleeds in a patient with hemophilia and 48 
inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018. 49 
31. Novo Nordisk A/S. A Trial Evaluating the Efficacy and Safety of Prophylactic 50 
Administration of Concizumab in Haemophilia A and B Patients With Inhibitors 51 
H[SORUHUhttps://clinicaltrials.gov/ct2/show/NCT03196284; 2017. 52 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
15 
 
32. Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-1 
tissue factor pathway inhibitor antibody, induces increased thrombin generation in 2 
plasma from haemophilia patients and healthy subjects measured by the thrombin 3 
generation assay. Haemophilia. 2017 Sep;23(5):769-76. 4 
33. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in 5 
Hemophilia A or B with RNAi Therapy. The New England journal of medicine. 2017 6 
Aug 31;377(9):819-28. 7 
34. Negrier C, Ragni MV, Georgiev P, et al. Perioperative management in patients 8 
with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting 9 
antithrombin for the treatment of hemophilia. Haemophilia. 2018 February;24 10 
(Supplement 1):27. 11 
35. Collins P, Liesner R, Makris M, et al. Treatment of bleeding episodes in 12 
haemophilia A complicated by a factor VIII inhibitor in patients receiving 13 
Emicizumab. Guidance from UKHCDO Inhibitor Working Party and Executive 14 
Committee.  2018  [cited 03/05/2018]; Available from: http://www.ukhcdo.org/wp-15 
content/uploads/2018/01/UKHCDO-guideline-for-treatment-of-bleeds-whilst-on-16 
Emicizumab-10.1.18-fi....pdf 17 
36. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin 18 
generation test for dose monitoring of bypassing therapy in hemophilia patients with 19 
inhibitors undergoing elective surgery. Blood. 2010 Dec 16;116(25):5734-7. 20 
37. Querol-Giner M, Perez-Alenda S, Iradi A, et al. Synoviorthesis in the 21 
Treatment of Recurrent Hemarthrosis in Haemophilia Patients with Inhibitors. 22 
Haemophilia. 2016;22:24. 23 
38. Antmen BA, Sasmaz I, Karagun, B.S., et al. The usage of recombinant 24 
activated factor VII (RFVIIA) during major and minor surgeries in severe hemophilia 25 
patients with inhibitor. XXV Congress of the International Society on Thrombosis and 26 
Haemostasis, 2015:1±997. 27 
39. Antmen B, Sasmaz I, Karagun B, et al. Circumcision in patients with 28 
hemophilia and the other bleeding disorders in southern part of Turkey. Haemophilia. 29 
2018 February;24 (Supplement 1):61. 30 
40. Bensadok M, Chennoukh WK, Aboura C, et al. Haemophilia with inhibitors, 31 
update from Algiers experience, about one center. XXV Congress of the International 32 
Society on Thrombosis and Haemostasis, 2015:1±997. 33 
41. Carulli C, Rizzo AR, Linari S, et al. Joint replacements for severe haemophilic 34 
arthropathy in patients with inhibitors: A long-term experience at a single institution. 35 
Blood Transfusion. 2017 November;15 (Supplement 4):s546. 36 
42. Caviglia H, Candela M, Galatro G, et al. Elective orthopaedic surgery for 37 
haemophilia patients with inhibitors: single centre experience of 40 procedures and 38 
review of the literature. Haemophilia. 2011 Nov;17(6):910-9. 39 
43. Caviglia H, Galatro G, Cambiaggi G, et al. Treatment of subchondral cysts in 40 
patients with haemophilia. Haemophilia 2016;22:292±7. 41 
44. Chapin J, Bamme J, Hsu F, Christos P, DeSancho M. Outcomes in Patients 42 
With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical 43 
Procedures. Clinical and applied thrombosis/hemostasis : official journal of the 44 
International Academy of Clinical and Applied Thrombosis/Hemostasis. 2017 45 
Mar;23(2):148-54. 46 
45. Ciavarella N, Antoncecchi S, Ranieri P. Efficacy of porcine factor VIII in the 47 
management of haemophiliacs with inhibitors. Br J Haematol. 1984 Dec;58(4):641-8. 48 
46. Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy 49 
and safety. Haemophilia. 2006 Jul;12(4):352-62. 50 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
16 
 
47. Freiburghaus C, Berntorp E, Ekman M, et al. Immunoadsorption for removal 1 
of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. 2 
Haemophilia. 1998 Jan;4(1):16-20. 3 
48. He Y, Zhou X, Cui H, et al. Surgical Management of Haemophilic 4 
Pseudotumors: Experience in a Developing Country. Journal of Investigative Surgery. 5 
2017 31 Oct:1-10. 6 
49. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic 7 
patients with inhibitors using recombinant factor VIIa. Haemostasis. 1996;26 Suppl 8 
1:118-23. 9 
50. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis 10 
of bleeding in various surgical procedures in hemophilic patients with factor VIII and 11 
factor IX inhibitors. Seminars in thrombosis and hemostasis. 2000;26(4):425-32. 12 
51. Jenkins PJ, Ekrol I, Lawson GM. Total knee replacement in patients with 13 
haemophilia: the Scottish experience. Scottish medical journal. 2013 Nov;58(4):223-14 
7. 15 
52. Kitchens CS. Surgery in hemophilia and related disorders. A prospective study 16 
of 100 consecutive procedures. Medicine. 1986 Jan;65(1):34-45. 17 
53. Kizilocak H, Ozdemir N, Ozcan R, Celkan T. Circumcision in children with 18 
haemophilia. Journal of Thrombosis and Haemostasis. 2016;14(Suppl 1):1±168. 19 
54. Lauroua P, Ferrer AM, GuÉRin V. Successful major and minor surgery using 20 
factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. 21 
Haemophilia. 2009;15(6):1300-7. 22 
55. Lim MY, Nielsen B, Lee K, et al. Rituximab as first-line treatment for the 23 
management of adult patients with non-severe hemophilia A and inhibitors. Journal 24 
of thrombosis and haemostasis : JTH. 2014 Jun;12(6):897-901. 25 
56. Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR. Use of porcine 26 
factor VIII for surgical procedures in hemophilia A patients with inhibitors. Seminars 27 
in hematology. 1993 Apr;30(2 Suppl 1):10-21. 28 
57. Mahasandana C, Patharathienskul D, Suvatte V. Hemophilia with factor VIII 29 
and factor IX inhibitors, incidence, bleeding problems and management. The 30 
Southeast Asian journal of tropical medicine and public health. 1993;24 Suppl 1:106-31 
12. 32 
58. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of 33 
prophylaxis and immune tolerance induction regimens in haemophilic children using 34 
fully implantable central venous catheters. Br J Haematol. 2008 May;141(5):689-95. 35 
59. Morado M, Jimenez-Yuste V, Villar A, et al. Complications of central venous 36 
catheters in patients with haemophilia and inhibitors. Haemophilia. 2001 37 
Nov;7(6):551-6. 38 
60. Nguyen T, Tran D, Dao H, et al. Surgical interventions in patients with 39 
hemophilia: Outcome of treatment at a single center in low-resource settings. 40 
Haemophilia. 2018 February;24 (Supplement 1):130. 41 
61. Nilsson IM, Hedner U, Ahlberg A, Larsson SA, Bergentz SE. Surgery of 42 
hemophiliacs--20 years' experience. World journal of surgery. 1977 Jan;1(1):55-66. 43 
62. O'Connell N, Mc Mahon C, Smith J, et al. Recombinant factor VIIa in the 44 
management of surgery and acute bleeding episodes in children with haemophilia 45 
and high responding inhibitors. Br J Haematol. 2002 Mar;116(3):632-5. 46 
63. Oldenburg J, Shima M, Kruse-Jarres R, et al. Bleeding events and safety 47 
outcomes in pediatric persons with hemophilia a with inhibitors: The first non-48 
interventional study (NIS) from a real-world setting. Blood Conference: 59th Annual 49 
Meeting of the American Society of Hematology, ASH. 2017;130(Supplement 1). 50 
64. Özdemir GN, Çelik E, Bulut M, et al. Circumcision in children with bleeding 51 
diathesis. Turkish Archives of Pediatrics. 2011;46:304±8. 52 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
17 
 
65. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E, et al. Surgery 1 
in haemophilic patients with inhibitor: 20 years of experience. Haemophilia. 2004 2 
Sep;10 Suppl 2:30-40. 3 
66. Rodriguez-Merchan EC. Total knee replacement in haemophilic arthropathy. 4 
The Journal of bone and joint surgery British volume. 2007 Feb;89(2):186-8. 5 
67. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, et al. Surgery in 6 
haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid 7 
experience. Haemophilia. 2010 May;16(102):84-8. 8 
68. Sasmaz I, Antmen B, Leblebisatan G, et al. Circumcision and complications in 9 
patients with haemophilia in southern part of Turkey: Cukurova experience. 10 
Haemophilia. 2012 May;18(3):426-30. 11 
69. Sasmaz I, Antmen BA, Karagun BS, et al. The experience of surgery with 12 
activated prothombin complex concentrates in haemophilia a patients with inhibitors. 13 
Haemophilia. 2015;21(Suppl 2):14±94. 14 
70. Sasmaz I, Antmen B, Karagun B, et al. The surgeries in hemophilia A patients 15 
with inhibitors. Haemophilia. 2018 February;24 (Supplement 1):84-5. 16 
71. Szczepanik AB, Wislawski S, Windyga J, et al. [Strategy for secure hemostasis 17 
in hemophilia patients undergoing surgery for malignant neoplasms]. Polski 18 
merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2009 19 
Nov;27(161):375-80. 20 
72. Serban M, Poenaru D, Pop L, et al. Surgery--a challenge in haemophiliacs 21 
with inhibitors. Hamostaseologie. 2009 Oct;29 Suppl 1:S39-41. 22 
73. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, 23 
randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with 24 
inhibitors undergoing surgery. Thrombosis and haemostasis. 1998 Nov;80(5):773-8. 25 
74. Shapiro A, Cooper DL. U.S. survey of surgical capabilities and experience with 26 
surgical procedures in patients with congenital haemophilia with inhibitors. 27 
Haemophilia. 2012 May;18(3):400-5. 28 
75. Smith OP. Recombinant factor VIIa in the management of surgery and acute 29 
bleeding episodes in children with haemophilia and high-responding inhibitors. 30 
Pathophysiology of haemostasis and thrombosis. 2002;32 Suppl 1:22-5. 31 
76. Solimeno LP, Mancuso ME, Pasta G, et al. Factors influencing the long-term 32 
outcome of primary total knee replacement in haemophiliacs: a review of 116 33 
procedures at a single institution. Br J Haematol. 2009 Apr;145(2):227-34. 34 
77. Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant 35 
activated factor VII use in surgical patients with congenital haemophilia with 36 
inhibitors or acquired haemophilia in Japan. Haemophilia. 2015 May;21(3):374-9. 37 
78. Gringeri A, Fischer K, Karafoulidou A, et al. Sequential combined bypassing 38 
therapy is safe and effective in the treatment of unresponsive bleeding in adults and 39 
children with haemophilia and inhibitors. Haemophilia. 2011 Jul;17(4):630-5. 40 
79. Lak M, Sharifian RA, Karimi K, Mansouritorghabeh H. Acquired hemophilia A: 41 
clinical features, surgery and treatment of 34 cases, and experience of using 42 
recombinant factor VIIa. Clinical and applied thrombosis/hemostasis : official journal 43 
of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2010 44 
Jun;16(3):294-300. 45 
80. Liozon E, Delaire L, Turlure P. Acquired inhibitor to factor VIII: C in non 46 
hemophiliacs (acquired hemophilia). Clinico-biologic study and management in nine 47 
patients. [French]. Annales de Medecine Interne 1997;148:477±90. 48 
81. Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. US experience with 49 
recombinant factor VIIa for surgery and other invasive procedures in acquired 50 
haemophilia: analysis from the Hemostasis and Thrombosis Research Society 51 
Registry. Haemophilia. 2016 Jan;22(1):e18-24. 52 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
18 
 
82. Novack A, St-Louis J, Greist A, et al. Perioperative management of bleeds 1 
with recombinant porcine FVIII in patients with acquired hemophilia A. Journal of 2 
Thrombosis and Haemostasis. 2015;13(Suppl 2):1997. 3 
83. Zulfikar B, Kilicoglu O, Atalar A, et al. Hemophilic Arthropathy in Inhibitor 4 
Positive Hemophilia Patients. Haemophilia. 2016;22:85-6. 5 
84. Boadas A, Fernandez-Palazzi F, De Bosch NB, Cedeno M, Ruiz-Saez A. 6 
Elective surgery in patients with congenital coagulopathies and inhibitors: experience 7 
of the National Haemophilia Centre of Venezuela. Haemophilia. 2011 May;17(3):422-8 
7. 9 
85. Carulli C, Rizzo AR, Martini C, et al. The orthopaedic treatment of haemophilic 10 
arthropathy in patients with inhibitors: A 15-year experience at a single Institution. 11 
Haemophilia. 2016;22(Suppl. 4):23. 12 
86. Castaman G, Linari S, Carulli C, Innocenti M. Short and long-term outcomes 13 
in hemophilia patients with inhibitors undergoing orthopedic prosthetic surgery. 14 
Blood. 2015;126(23):4704. 15 
87. Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL. Safety and efficacy 16 
of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate 17 
use and trial data supporting US label. Pediatric blood & cancer. 2016 18 
Oct;63(10):1822-8. 19 
88. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing 20 
activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs 21 
with inhibitors. Blood. 1983 Jan;61(1):36-40. 22 
89. Ju HY, Jang HL, Park YS. The efficacy of bypassing agents in surgery of 23 
hemophilia patients with inhibitors. Blood research. 2015 Sep;50(3):173-8. 24 
90. Kavakli K, Zulfikar H, Zulfikar B, et al. Efficacy of FEIBA for acute bleeding 25 
and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre 26 
registry in Turkey. Haemophilia. 2012 May;18(3):383-91. 27 
91. Linari S, Carulli C, Martini C. Short and long-term outcomes in hemophilia 28 
patients with inhibitors undergoing orthopedic prosthetic surgery. Haematologica. 29 
2015;100:26±7. 30 
92. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on 31 
the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. 32 
French FEIBA Study Group. Factor Eight Bypassing Activity. Thrombosis and 33 
haemostasis. 1997 Jun;77(6):1113-9. 34 
93. Negrier C, Lienhart A, Numerof R, et al. SURgical interventions with FEIBA 35 
(SURF): international registry of surgery in haemophilia patients with inhibitory 36 
antibodies. Haemophilia. 2013 May;19(3):e143-50. 37 
94. Polyanskaya T, Zorenko V, Karpov E, et al. Experience of recombinant 38 
activated factor VII usage during surgery in patients with haemophilia with inhibitors. 39 
Haemophilia. 2012 Nov;18(6):997-1002. 40 
95. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care 41 
centres using FEIBA(R) for surgeries in patients with inhibitors. Haemophilia. 2011 42 
Jan;17(1):28-34. 43 
96. Rodriguez-Merchan EC. Surgery in haemophilic patients with inhibitors. 44 
Haemophilia. 2004 Sep;10 Suppl 2:1-2. 45 
97. Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII 46 
activity and clinical efficacy of recombinant factor VIIa given by continuous infusion 47 
to patients with factor VIII inhibitors. Thrombosis and haemostasis. 2001 48 
Oct;86(4):954-8. 49 
98. Sasmaz I, Antmen B, Guvenc B, et al. Circumcision and complications in 50 
adolescent and adult patients wiith hemophilia in southern part of Turkey. 20th 51 
Congress Of The European Hematology Association. Vienna, Austria, 2015:1±804. 52 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
19 
 
99. Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients with factor 1 
VIII inhibitor: 10-year experience. World journal of surgery. 1996 Nov-2 
Dec;20(9):1171-81. 3 
100. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment 4 
during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian 5 
experience. Haemophilia. 2004 Sep;10 Suppl 2:41-5. 6 
101. Tjonnfjord GE. Surgery in patients with hemophilia and inhibitors: a review of 7 
the Norwegian experience with FEIBA. Seminars in hematology. 2006 Apr;43(2 Suppl 8 
4):S18-21. 9 
  10 
Final Draft ± Haemophilia Perioperative Monitoring 16 April 2019 
20 
 
FIGURE LEDGEND 1 
Figure 1. Systematic Review of Clinical Studies 2 
Only articles discussing laboratory monitoring were extracted 3 
Records identified through database 
searches
n=1,481
Embase and MEDLINE (n=1,383)
Cochrane Library (n=98)
CDSR (n=4)
DARE (n=2)
CENTRAL (n=92)
Records screened at 
title/abstract review
n=1,358
Duplicates n=123
Records excluded at 
title/abstract review*
n=1,189
Duplicate (n=17)
Language/Non-humans 
(n=88)
Population (n=690)
Outcomes (n=101)
Study design (n=293) Full texts reviewed
n=169
Records excluded after 
full text review* 
n=88
Duplicate (n=6)
Language (n=2)
Study design (n=34)
Population (n=17)
Intervention (n=29)
Records included in systematic review
n=86 publications included
From database searches (n=81)
From supplementary searches (n=5)
Congress searches (n=4)
Reference lists (n=1)
Records extracted in systematic review
Q SXEOLFDWLRQVH[WUDFWHG
From database searches (n=23)
From supplementary searches (n=1)
Records identified in 
supplementary searches
n=552
Congress searches (n=502)
Reference lists (n=50)
Records excluded from 
supplementary searches
n=547
Congress searches (n=498)
Reference lists (n=49)
Records included from 
supplementary searches
n=5
Congress searches (n=4)
Reference lists (n=1)
)LJXUH
Table 1. Studies Included Following Full Text Screening 
Study Study Type Country Monitoring reported 
Congenital haemophilia  
Alenda et al. 2016[37] Observational  Spain  Not reported 
Antmen et al. 2015[38]  Observational Turkey Not reported 
Antmen et al. 2018[39] Observational Turkey Not reported 
Balkan et al. 2010[12] Observational  Turkey Laboratory monitoring  
Bensadok et al. 2015[40] Observational Algeria Not reported  
Carulli et al. 2017[41] Observational Italy Not reported 
Caviglia et al. 2011[42] Observational Argentina Not reported 
Caviglia et al. 2016[43] Observational Argentina Not reported 
Chapin et al. 2017[44]  Observational USA Not reported  
Ciavarella et al. 1984[45] Interventional  Italy  Not reported  
Danielson et al. 2017[24] Observational Finland Laboratory monitoring 
Dimichele et al. 2006[46] Observational USA and Europe Not reported  
Freiburghaus et al. 
1998[47] 
Observational Sweden Not reported  
He et al. 2017[48] Observational China Not reported 
+ROPVWU঍PHWDO
2012[22] 
Interventional  Norway and Sweden Laboratory monitoring  
Ingerslev et al. 1996[49] Observational Multiple Laboratory monitoring 
Ingerslev et al. 2000[50]  Observational Denmark Not reported  
Jenkins et al. 2013[51] Observational UK Not reported 
Karagun et al. 2016  Observational  Turkey Not reported 
Kitchens et al. 1986[52] Observational USA Not reported  
Kizilocak et al. 2016[53] Observational Turkey  Not reported 
Kruse-Jarres et al. 
2017[27] 
Interventional Multiple Not reported 
Lauroua et al. 2009[54] Observational France Both [clinical and laboratory 
monitoring] 
Lim et al. 2014[55] Observational USA Not reported  
7DEOH
Study Study Type Country Monitoring reported 
Lozier et al. 1993[56] Observational Multiple Not reported 
Ludlam et al. 2003[10] Interventional  UK and Italy Laboratory monitoring  
Mahasandana et al. 
1993[57] 
Observational Thailand  Not reported 
Mancuso et al. 2008[58] Observational Italy  Not reported  
Morado et al. 2001[59] Observational Spain Not reported  
Negrier et al. 2018[34] Interventional Multiple Not reported 
Nguyen et al. 2018[60] Observational Vietnam Not reported 
Nilsson et al. 1977[61] Observational Sweden Laboratory monitoringȘ 
O'Connell et al. 2002[62] Observational Ireland and UK Clinical monitoring 
Oldenburg et al. 
2017[63] 
Observational Multiple Not reported 
Ozdemir et al. 2011[64] Observational Turkey Not reported  
Pruthi et al. 2007[19] Interventional  USA Laboratory monitoring  
Quintana-Molina et al. 
2004[65] 
Observational Spain Laboratory monitoring  
Rodriguez-Merchan et al. 
2007[66] 
Observational Spain Not reported 
Rodriguez-Merchan et al. 
2010[67] 
Observational Spain Not reported 
Sasmaz et al. 2012[68] Observational Turkey Not reported 
Sasmaz et al. 2015[69] Observational Turkey Not reported  
Sasmaz et al. 2018[70] Observational Turkey Not reported 
Szczepanik et al. 
2018[71] 
Observational Poland Not reported 
Serban et al. 2009[72] Observational Romania Not reported 
Shapiro et al. 1998[73] Interventional  USA Laboratory monitoring  
Shapiro et al. 2012[74] Observational USA Not reported 
Smith et al. 2002[75] Observational Ireland and UK Both [clinical and laboratory 
monitoring] 
Study Study Type Country Monitoring reported 
Solimeno et al. 2009[76] Observational Italy  Not reported  
Takedani et al. 2010[77] Observational Japan Not reported  
Acquired haemophilia  
Gringeri et al. 2011[78]  Observational Europe Laboratory monitoring 
Lak et al. 2010[79] Observational Iran Laboratory monitoring 
Liozon et al. 1997[80] Observational France Laboratory monitoring 
Ma et al. 2016[81] Interventional USA Not reported 
Novack et al. 2015[82] Observational Multiple  Not reported 
Both congenital and acquired haemophilia  
Atalar et al. 2016[83]  Observational  Turkey  Not reported 
Boadas et al. 2011[84]  Observational  Venezuela Both [clinical and laboratory 
monitoring]Á 
Carulli et al. 2016[85] Observational Italy Not reported 
Castaman et al. 2015[86] Observational Italy Not reported 
Croteau et al. 2016[87] Interventional  USA Not reported 
Furukawa et al. 2015[20] Interventional  Japan  Laboratory monitoring  
Gatti et al. 1984[13] Interventional  Italy  Laboratory monitoring  
Habermann et al. 
2004[23] 
Observational Germany Laboratory monitoring 
Hilgartner et al. 1983[88] Observational USA Not reported 
Ju et al. 2015[89]  Observational South Korea Clinical monitoring  
Kavakli et al. 2012[90] Observational Turkey Not reported 
Kraut et al. 2007[14]  Observational USA Laboratory monitoring 
Linari et al. 2015[91]  Observational Italy  Not reported 
Mancuso et al. 2016[25] Observational Italy  Laboratory monitoring  
Mauser-Bunschoten et al. 
1998[16] 
Observational Netherlands and 
Belgium  
Both [clinical and laboratory 
monitoring] 
Mauser-Bunschoten et al. 
2002[17] 
Observational Netherlands Both [clinical and laboratory 
monitoring] 
Negrier et al. 1997[92] Observational France Not reported 
Study Study Type Country Monitoring reported 
Negrier et al. 2013[93] Observational Worldwide: Colombia, 
France, Germany, Italy, 
South Korea, Sweden 
and the UK 
Both [clinical and laboratory 
monitoring] 
Polyanskaya et al. 
2012[94]  
Observational Russia Clinical monitoring  
Rangarajan et al. 
2011[95]  
Observational UK Clinical monitoring 
Rodriguez-Merchan et al. 
2004[96]  
Observational Worldwide Not reported 
Rodriguez-Merchan et al. 
2007[66]  
Observational Spain Not reported 
Santagostino et al. 
2001[97]  
Observational Italy  Laboratory monitoring  
Sasmaz et al. 2015[98]  Observational Turkey  Not reported  
Scharf et al. 1996[99] Observational Poland Not reported  
Scharrer et al. 1999[15] Interventional  Germany Both [clinical and laboratory 
monitoring] 
Serban et al. 2014[21] Observational Romania Both [clinical and laboratory 
monitoring] 
Smith et al. 2001[18] Interventional Unclear Both [clinical and laboratory 
monitoring] 
Szczepanik et al. 
2009[71] 
Observational Poland Not reported 
Takedani et al. 2015[77] Observational Japan Clinical monitoring  
Tjonnfjord et al. 2004/ 
Tjonnfjord et al. 
2006[100, 101] 
Observational Norway  Laboratory monitoring  
Outcomes not reported separately for inhibitor patients so data not extracted; ÁNo monitoring results 
reported so data not extracted 
Table 2. Overview of Studies Reporting Perioperative Laboratory Monitoring 
Study Study design Patients Procedures Haemostatic treatment Haemostatic outcome 
Balkan C et al. 
2010[12] 
Single-centre, 
retrospective 
observational study 
30 HA patients with high 
responding inhibitors 
11 major 
42 minor 
x aPCC, or 
x rFVIIa, or 
x Sequential use of aPCC 
and rFVIIa  
x aPCC: 22/22 (100%) 
bleeding controlled 
x rFVIIa: 31/33 (94%) 
bleeding controlled 
Danielson H et al. 
2017[24] 
Single-centre, 
retrospective 
observational study 
6 HA patients with 
inhibitors (n=2 low-
responding, n=4 high-
responding) 
15 orthopaedic x Cryoprecipitate, or 
x Coagulation FVIII 
(pdFVIII or rFVIII), or 
x aPCC, or 
x rFVIIa (post-treatment 
switch in some individual 
cases) 
8/15 (53%) bleeding controlled 
(UDWHGDVµJRRG¶LQGLFDWLQJQR
difference in bleeding compared 
to normal arthroplasty)  
Furukawa S et al. 
2015[20] 
Single-centre, 
prospective 
interventional study 
8 HA patients with 
inhibitors 
8 elective x rFVIIa, or 
x aPCC 
8/8 (100%) bleeding controlled 
Gatti L et al. 
1984[13] 
Single-centre, 
prospective, 
uncontrolled 
interventional study 
5 HA patients with 
inhibitors 
3 minor 
2 major 
x Bolus porcine FVIII 
(Hyate:C) (minor dental), 
or 
x Continuous porcine FVIII 
(Hyate:C) (major) 
2/2 (100%) bleeding controlled 
(only reported for major 
surgery) 
Habermann B et 
al. 2004[23] 
Single-centre, 
retrospective 
observational study 
4 HA patients with 
inhibitors 
6 orthopaedic AnvitoffTM (containing TXA) 
in combination with: 
x bolus FVIII (low 
inhibitor titre) 
x immunoabsorbant 
therapy (TherasorbTM) 
followed by bolus FVIII 
(high inhibitor titre) 
x continuous rFVIIa 
infusion when inhibitor 
titres rose/could not be 
eliminated or FVIII 
response decreased 
5/6 (83%) bleeding controlled 
+ROPVWU঍P0HW
al. 2012[22] 
Two-centre, 
prospective 
interventional study 
6 HA patients with high 
responding inhibitors 
2 minor  
5 major 
Bolus aPCC in combination 
with TXA 
6/7 (86%) bleeding controlled 
7DEOH
Study Study design Patients Procedures Haemostatic treatment Haemostatic outcome 
Ingerslev J. et al. 
1996[49] 
Multicentre, 
retrospective 
observational study 
11 HA patients and 1 HB 
patient with inhibitors 
13 major Bolus rFVIIa 12/12 (100%) bleeding 
controlled (Outcome not 
reported in n=1 case) 
Kraut EH et al. 
2007[14] 
Multicentre, 
retrospective chart 
review 
6 HA patients with 
inhibitors 
21 various x Bolus aPCC monotherapy, 
or 
x Bolus rFVIIa 
monotherapy, or 
x Bolus/continuous 
combination therapy 
14/21 (67%) bleeding 
controlled 
Lauroua P et al. 
2009[54] 
 
 
 
Single-centre, 
retrospective 
observational study 
7 HA patients with 
inhibitors  
8 major elective 
2 major emergency 
2 minor elective 
Bolus aPCC as first-line 
treatment 
Haemostatic outcomes were 
consistent with non-
coagulopathic patients 
undergoing similar procedures 
Ludlam A et al. 
2003[10] 
Prospective, 
interventional study 
9 HA patients with 
inhibitors 
9 major orthopaedic Continuous rFVIIa 8/9 (88.9%) bleeding controlled 
at end of surgery 
Mancuso ME et al. 
2016[25] 
Single-centre, 
prospective, 
observational study 
10 HA patients with 
inhibitors 
11 major orthopaedic Bolus doses of: 
x rFVIIa 
x aPCC 
x Sequential therapy with 
rFVIIa and aPCC 
10/11 (91%) bleeding 
controlled 
Mauser-
Bunschoten EP et 
al. 1998[16] 
Multicentre, 
retrospective 
observational study 
3 HA patients with 
inhibitors 
2 dental extraction 
2 hip arthroplasty 
Continuous rFVIIa 3/4 (75%) bleeding controlled 
Mauser-
Bunschoten EP et 
al. 2002[17] 
Multicentre, 
prospective 
observational study 
4 HA patients and 1 HB 
patient with inhibitors 
2 synovectomy 
4 dental extraction 
1 orthopaedic surgery 
Continuous rFVIIa NR (except 2 dental extractions 
UDWHGµLQHIIHFWLYH¶DQGUDWHG
µSDUWLDOO\HIIHFWLYH¶ 
Négrier C et al. 
2013[93] 
Multicentre, 
prospective, 
observational study 
18 HA patients and 2 HB 
patients with inhibitors 
35 various (including 
procedures performed 
on n=4 acquired 
haemophilia patients) 
Bolus aPCC 31/34 (91%) bleeding 
FRQWUROOHGUDWHGDVµH[FHOOHQW¶
RUµJRRG¶IXOOSRSXODWLRQ
including acquired haemophilia 
patients; concomitant 
medication documented in 
n=34/35 surgical procedures) 
Pruthi RK et al. 
2007[19] 
Multicentre, 
prospective 
interventional study 
24 HA/HB patients with 
inhibitors (A/B subgroups 
not specified) 
24 elective surgery Bolus and continuous 
infusion of rFVIIa 
17/23 (74%) bleeding 
controlled overall (n=1 patient 
excluded from efficacy analysis) 
Study Study design Patients Procedures Haemostatic treatment Haemostatic outcome 
Quintana-Molina 
M et al. 2004[65] 
 
Single-centre, 
retrospective 
observational study 
45 HA patients 3 HB 
patients with inhibitors 
10 major elective and 
emergency  
54 minor elective and 
emergency 
Bolus doses of: 
x rFVIIa, or 
x aPCC, or 
x FVIII concentrate 
x rFVIIa: 14/18 (78%) 
bleeding controlled 
x aPCC: 31/32 (97%) bleeding 
controlled 
x FVIII concentrate: 15/15 
(100%) bleeding controlled 
(based on outcomes reported in 
article tables) 
Santagostino E et 
al. 2001[97] 
Multicentre, 
prospective, 
observational study 
25 HA patients with 
inhibitors (unclear how 
many had surgery) 
11 major 
14 minor 
Continuous rFVIIa 6XUJLFDOSDWLHQWV¶UHVXOWVQRW
reported separately 
Scharrer I. 
1999[15] 
Multicentre, 
prospective 
interventional study 
19 HA/HB patients with 
inhibitors (A/B subgroups 
not specified) 
5 major 
17 minor 
(full population including 
patients with acquired 
inhibitors/FVII 
deficiency) 
Bolus rFVIIa 100% minor/60% major 
surgical procedures bleeding 
controlled (during surgery) 
Serban M et al. 
2014[21] 
Single-centre, 
retrospective 
observational study 
13 HA/B patients with 
inhibitors (not clear 
whether A or B) 
Invasive orthopaedic (n 
NR) 
Bolus doses and continuous 
infusion of: 
x FVIII/FIX concentrates 
x rFVIIa 
Reported but not for population 
of interest 
Shapiro AD et al. 
1998[73] 
Multicentre, 
prospective 
interventional study 
25 HA patients and 3 HB 
patients with inhibitors 
29 (including 1 
procedure for a patient 
with acquired 
haemophilia): 
11 major 
18 minor 
Bolus rFVIIa 23/29 (79%) bleeding 
controlled (may include 1 
acquired haemophilia patient¶V
procedure) 
Smith MP et al. 
2001[18] 
Multicentre, 
prospective 
interventional study 
6 HA patients with 
inhibitors 
6 major Bolus dose followed by 
continuous infusion of rFVIIa 
2/6 bleeding controlled 
Smith OP et al. 
2002[75] 
Two-centre, 
retrospective chart 
review 
12 HA patients with 
inhibitors 
19 CVAD 
insertion/removal 
1 multiple dental 
extraction 
Bolus rFVIIa 20/20 (100%) bleeding 
controlled (n=2 cases of minor 
bleeding after treatment had 
ended were resolved with re-
treatment of rFVIIa) 
Tjonnfjord GE. 
2004, 2006[100, 
101] 
Single-centre, 
retrospective 
observational study 
8 HA patients with 
inhibitors 
12 minor 
6 major 
Bolus aPCC 18/18 (100%) bleeding 
controlled 
aPCC: Activated prothrombin complex concentrate; CVAD: Central venous access device; FIX: Factor IX; FVII: Factor VII; FVIII: Factor VIII; 
HA: Haemophilia A; HB: Haemophilia B; NR: Not reported; pdFVIII: Plasma-derived factor VIII; rFVIIa: Recombinant factor VIIa; rFVIII: 
Recombinant factor VIII; TXA: Tranexamic acid 
 
Table 3: Routine Laboratory Testing 
Study Monitoring methods 
 
Monitoring results 
Balkan C et 
al. 2010[12] 
Laboratory assessment (post-operative) of: 
x Platelet count 
x PT 
x APTT 
x Fibrinogen 
x D-dimer 
x APTT did not return to normal by using the haemostatic agents  
x Significant shortening of PT 
Gatti L et al. 
1984[13] 
Laboratory assessment of: 
x Clinical effectiveness 
x The prevalence of anamnestic antibody responses and of severe or 
milder side effects 
x Platelet counts 
x Haematocrit 
NR 
Habermann 
B et al. 
2004[23] 
Laboratory assessment of: 
x D-dimer 
x Only on the day of surgery was a slight increase of the D-dimer level 
seen. On the postoperative days, the D-dimer levels were within the 
normal range. 
Ingerslev J. 
et al. 
1996[49] 
Laboratory assessment of: 
x Platelet count 
x PT 
x APTT 
x Fibrinogen 
x D-dimer 
x ATIII 
x Small reductions in platelet numbers 
x Significantly shortened PT following infusion 
x APTT shortened in nearly all patients 
x Insignificant changes in fibrinogen 
x All but one D-dimer sample showed results below the limits of 
specified abnormality 
x ATIII showed no tendency to decrease 
Kraut EH et 
al. 2007[14] 
Laboratory assessment, including platelet function analysis, of: 
x D-dimer levels 
x Haemoglobin level 
x Aggregation 
x aPCC treatment was reduced after monitoring indicated an elevation in 
D-dimer levels 
Lauroua P et 
al. 2009[54] 
Consumption coagulopathy and thrombogenicity evaluated with 
laboratory assessment of: 
x Platelets 
x Fibrinogen 
x D-dimer or fibrinogen and fibrin degradation products 
x Haemoglobin level 
x Monitoring of D-dimer, fibrinogen and fibrin degradation products 
showed no consistent activation of coagulation or increase in 
fibrinolysis 
x Neither platelet consumption nor fibrinogen depletion observed post-
operatively 
x Haemoglobin remained stable above 8 g/dL in most cases 
Ludlam A et 
al. 2003[10] 
Laboratory assessment of: 
x Complete blood counts 
x Fibrinogen 
x D-dimer 
x ATIII (assessed by chromogenic determination) 
x ATIII, fibrinogen and platelet counts fluctuated but did not decline 
progressively 
x During the first 72 h of infusion, mean platelet count decreased; Mean 
ATIII decreased between wound closure and at 72 h 
7DEOH
Study Monitoring methods 
 
Monitoring results 
Mancuso ME 
et al. 
2016[25] 
Laboratory assessment of: 
x Fibrinogen (Functional Clauss method) 
x D-dimer (Latex enhanced turbidimetric immunoassay) 
x PT (PT-based one-stage assay) 
x D-dimer significantly increased over the first four post-operative days 
x Fibrinogen slightly decreased on the first post-operative day, then 
increased for the following three post-operative days 
x PT increased slightly in aPCC-treated patients over four post-operative 
days  
Mauser-
Bunschoten 
EP et al. 
1998[16] 
Laboratory assessment of: 
x PT 
 
NR 
Mauser-
Bunschoten 
EP et al. 
2002[17] 
Laboratory assessment of: 
x PT 
NR 
Négrier C et 
al. 2013[93] 
Laboratory assessment of: 
x Haemoglobin 
x Red blood cell count 
x Haematocrit  
x Liver enzyme levels 
x Abnormal, significant haemoglobin levels were observed in 5 patients 
with inhibitors 
Pruthi RK et 
al. 2007[19] 
Laboratory assessment of: 
x Fibrinogen 
x D-dimer 
x PT 
x No statistically significant differences between pre- and postoperative 
platelet counts, fibrinogen, D-dimer and F 1.2 concentrations between 
bolus infusion, continuous infusion or control subjects 
Quintana-
Molina M et 
al. 2004[65] 
 
Laboratory assessment (postoperative and control tests at least every 48 
hours) of: 
x Platelet count (obtained by impedance and optically) 
x PT and cephaline time (monitored by two apparatuses based on 
different techniques, either optical density or magnetic force) 
x Fibrinogen (Clauss method) 
x D-dimer (turbidimetry) 
NR 
Santagostino 
E et al. 
2001[97] 
Laboratory assessment of: 
x PT 
x APTT 
x Fibrinogen 
x D-dimer 
x Platelet count 
x Platelet count decreased during 2 courses of treatment given for 
knee replacement 
Scharrer I. 
1999[15] 
Laboratory assessment of PT and APTT plus: 
x Fibrinogen, or 
x Platelets, or 
NR 
(Laboratory results only collected if considered necessary by the 
investigator and adverse event had occurred) 
Study Monitoring methods 
 
Monitoring results 
x Thrombin-antithrombin complex, or 
x D-dimer, or 
x Fibrino-peptide A, or 
x Fibrin-degradation products, or 
x Fibrin monomer, or 
x ATIII, or 
x Į-antiplasmin 
Shapiro AD 
et al. 
1998[73] 
Laboratory assessment of: 
x PT 
x Fibrinogen 
x D-dimer 
x ATIII 
x Platelet count 
x Mean PT decreased 
x D-dimer levels increased in 83% of patients during the first 48 h 
postoperatively 
x No changes in ATIII 
x Mean fibrinogen levels increased 
x No change in platelet levels 
Smith MP et 
al. 2001[18] 
Laboratory assessment of: 
x International normalised ratio 
x Fibrinogen (Clauss method) 
x ATIII 
x Automated full blood counts 
x D-dimer 
x ATIII, fibrinogen and platelet counts were not observed to decline 
Smith OP et 
al. 2002[75] 
Laboratory assessment of: 
x PT levels 
x PT shortened to lower limit of normal following rFVIIa treatment 
x Some haemoglobin levels dropped below 8 g/dL in patients who 
experienced bleeding epsiodes 
Tjonnfjord 
GE. 2004, 
2006[100, 
101] 
Laboratory assessment of: 
x PT 
x APTT 
x Fibrinogen 
x D-dimer 
PT shortened 
aPCC: Activated prothrombin complex concentrate; APTT: Activated partial thromboplastin time; ATIII: Antithrombin; NR: Not reported; PT: 
Prothrombin time  
 
Table 4: Factor VII Monitoring 
Study Haemostatic 
treatment 
Reported factors 
monitored 
Method of monitoring Monitoring results 
Ingerslev J. et 
al. 1996[49] 
Bolus rFVIIa Levels of post-infusion FVII:C Laboratory assessment NR 
Ludlam A et al. 
2003[10] 
Continuous rFVIIa x FVII:C 
x FVIIa:C levels 
x Plasma FVII:C was assessed by an 
automated one-stage FVII clot 
method on an automated 
laboratory analyser 
x FVIIa:C was assessed using a 
specific automated assay 
x Mean (range) FVII:C levels: 
o Effective haemostasis, end of surgery: 37 
IU/ml, (29±51 IU/ml), n=8 
o Ineffective haemostasis, end of surgery: 
27 IU/ml, n=1 
o Effective haemostasis, 8h after wound 
closure: 38 IU/ml (24±79 IU/ml), n=5 
o Partially effective haemostasis, 8h after 
wound closure: 42 IU/ml, (37±57 IU/ml), 
n=4 
x Mean (range) FVIIa:C levels: 
o Effective haemostasis, end of surgery: 50 
IU/ml, (37±59 IU/ml), n=8 
o Ineffective haemostasis, end of surgery: 
40 IU/ml, n=1 
o Effective haemostasis, 8h after wound 
closure: 52 IU/ml (37±74 IU/ml), n=5 
o Partially effective haemostasis, 8h after 
wound closure: 61 IU/ml, (38±82 IU/ml), 
n=4 
x FVII:C was >30 IU/ml at time of all but one 
bleeds 
Mauser-
Bunschoten EP 
et al. 1998[16] 
Continuous rFVIIa Plasma FVIIa levels FVIIa: one-stage coagulation assay x FVIIa levels maintained above 10 U/ml 
through flow rate adjustment 
Mauser-
Bunschoten EP 
et al. 2002[17] 
Continuous rFVIIa Plasma FVIIa levels FVIIa: one-stage coagulation assay NR 
Pruthi RK et al. 
2007[19] 
Bolus and continuous 
infusion of rFVIIa 
FVII:C Samples for FVII:C were collected 
within 30 min prior to and at 10 min 
DIWHUWKHLQLWLDOǋJNJU)9,,a bolus 
infusion, at 0, 8, 24, 48 and 72 h after 
wound closure and daily from post-
operative day 4 ±10 or until discharge 
(and prior to any supplemental bolus 
x At wound closure, FVII:C levels were higher in 
continuous vs. bolus infusion patients, which 
as sustained through 72 h but not statistically 
significant 
x In subjects for whom therapy was ineffective, 
FVII:C levels were in excess of 30 IU/ml at the 
time therapy was declared ineffective 
7DEOH
Study Haemostatic 
treatment 
Reported factors 
monitored 
Method of monitoring Monitoring results 
infusion of rFVIIa). FVII:C was 
measured in a central laboratory 
Santagostino E 
et al. 2001[97] 
Continuous rFVIIa FVII:C One-stage coagulation assay x FVII:C levels were significantly higher during 
continuous infusion courses given for major 
surgery than minor surgery 
x rFVIIa clearance was significantly lower in 
courses given for major surgery than for minor 
surgery 
Shapiro AD et al. 
1998[73] 
Bolus rFVIIa FVII:C Laboratory analysis of blood sample x FVII:C could not be analysed in terms of 
haemostatic outcome due to timings of blood 
sampling 
Smith MP et al. 
2001[18] 
Bolus dose followed by 
continuous infusion of 
rFVIIa 
FVII:C Laboratory assessment x Target FVII:C of 10 IU/dl was found to be 
insufficient to prevent bleeding 
FVII:C: Factor VII coagulation activity; FVIIa:C: Factor VIIa coagulation activity; FVIIa: Factor VIIa; NR: Not reported; rFVIIa: Recombinant 
factor VIIa 
 
 
Table 5: TEG/ROTEM Analysis 
Study Haemostatic 
treatment 
Reported factors 
monitored 
Method of monitoring Monitoring results 
Furukawa S et 
al. 2015[20] 
x rFVIIa, or 
x aPCC 
Coagulation process: 
x Clotting time 
x Clot formation time 
ROTEM x Clotting time and clot formation time ROTEM 
parameters shortened significantly after 
infusion of bypassing products 
x Clot formation time was shorter than normal in 
most cases after treatment with rFVIIa 
+ROPVWU঍P0HW
al. 2012[22] 
Bolus aPCC in 
combination with TXA 
Whole blood coagulation 
profiles 
ROTEM 
 
x During surgery, TEG showed significant 
improvement in CT, MaxVel and tMaxVel after 
aPCC and TXA and MCF increased towards 
normal  
x No significant difference in CT or MaxVel 
between different TXA concentrations 
x Significant increase in clot stability, shown by 
MCF, in a dose-dependent manner 
Serban M et al. 
2014[21] 
Bolus doses and 
continuous infusion of: 
x FVIII/FIX 
concentrates 
x rFVIIA 
FVIII/FIX activity TEG NR 
aPCC: Activated prothrombin complex concentrate; CT: Clotting time; FIX: Factor IX; FVIII: Factor VIII; MaxVel: Maximum velocity of clot 
formation; MCF: Maximum clot formation; NR: Not reported; rFVIIa: Recombinant factor VIIa; ROTEM: Rotational thromboelastometry; TEG: 
Thromboelastography; tMaxVel: Time until maximum velocity; TXA: Tranexamic acid 
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Table 6: Factor VIII:C 
Study Haemostatic 
treatment 
Reported factors 
monitored 
Method of monitoring Monitoring results 
Porcine FVIII:C 
Gatti L et al. 
1984[13] 
x Bolus porcine FVIII 
(Hyate:C) (minor 
dental), or 
x Continuous porcine 
FVIII (Hyate:C) 
(major) 
x The antibody cross-
reactivity with porcine 
FVIII  
x The relationship between 
preinfusion antibody titre, 
FVIII dosage given and its 
postinfusion plasma levels  
x The problems of 
µUHVLVWDQFH¶ 
 
x Platelet counts and haemotocrits 
were measured with standard 
methods 
x FVIII coagulant activity measured by 
a one-stage method 
x Anti-human FVIII antibody measured 
in fresh plasma by the Bethesda 
assay method 
x Anti-porcine FVIII antibody 
measured using method based on 
same principles as Bethesda assay 
x Haemostatic efficacy was dependent on 
achieving and maintaining target levels of 
FVIII:C (40-50 U/dl for dental surgery) 
x FVIII:C was used to identify cases of 
µUHVLVWDQFH¶WRE\SDVVLQJWKHUDS\ZLWK
treatment adjusted as appropriate 
Human FVIII:C 
Danielson H et 
al. 2017[24] 
x Cryoprecipitate, or 
x Coagulation FVIII 
(pdFVIII or rFVIII), 
or 
x aPCC, or 
x rFVIIa (post-
treatment switch in 
some individual 
cases) 
x FVIII:C 
x Development of 
disseminated 
intravascular 
coagulation, anaemia, or 
thrombocytopenia 
Routine blood coagulation test x One patient experienced a decline in FVIII:C 
which led to a treatment switch 
Habermann B et 
al. 2004[23] 
AnvitoffTM (containing 
TXA) plus bolus FVIII 
or continuous rFVIIa 
infusion 
FVIII:C levels and inhibitors Laboratory assessment x A decrease of FVIII levels down to zero was 
measured on days 4±6 in all patients 
substituted with FVIII. Simultaneously an 
increase of the inhibitors against FVIII was 
noticed 
+ROPVWU঍P0HW
al. 2012[22] 
Bolus aPCC in 
combination with TXA 
FVIII:C One-stage clotting assay (FVIII activity) NR 
Serban M et al. 
2014[21] 
Bolus doses and 
continuous infusion of: 
x FVIII/FIX 
concentrates 
x rFVIIa 
FVIII/FIX activity Laboratory assessment NR 
aPCC: Activated prothrombin complex concentrate; FIX: Factor IX; FVIII: Factor VIII; FVIII:C: Factor VIII coagulation activity; NR: Not 
reported; pdFVIII: Plasma-derived factor VIII; rFVIIa: Recombinant factor VIIa; rFVIII: Recombinant factor VIII; TXA: Tranexamic acid 
 
7DEOH
Table 7: Thrombin Generation 
Study Haemostatic 
treatment 
Factors monitored Method of monitoring Monitoring results 
+ROPVWU঍P
M et al. 
2012[22] 
Bolus aPCC in 
combination with 
TXA 
LT, ETP, peak and ttPeak TGA (on platelet-poor plasma) x TGA showed shortened LT, ttPeak and a 
higher ETP and peak after aPCC + TXA 
administration compared to baseline, but not 
exceeding the values of healthy controls 
Mancuso ME 
et al. 
2016[25] 
Bolus doses of: 
x rFVIIa 
x aPCC 
x Sequential 
therapy with 
rFVIIa and aPCC 
Platelet count TGA x No significant difference was found in TGA 
values (PRP and PPP) measured during the 
postoperative period by comparing 
procedures with (n=7) and without (n=4) 
bleeding complications (data not shown) 
aPCC: Activated prothrombin complex concentrate; ETP: Endogenous thrombin potential; LT: Lagtime; PRP: Platelet-rich plasma; PPP: Platelet-
poor plasma; rFVIIa: Recombinant factor VIIa; TGA: Thrombin generation assay; ttPeak: Time to peak; TXA: Tranexamic acid 
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SUPPLEMENTARY DATA 1 
Supplementary Table 1. Search Terms for MEDLINE and Embase (Searched 2 
via the Ovid SP Platform) 3 
Term group # Searches Hits 
 Patients with haemophilia 
1 exp *HEMOPHILIA A/ or exp *HEMOPHILIA B/ 32,171 
2 (hemophilia* or haemophilia*).tw. 49,984 
3 1 or 2 54,867 
 Intervention 
4 
(surger* or surgic* or operat* or procedure* or 
dental).tw. 
6,877,475 
5 exp *surgical procedures, operative/ 3,914,616 
6 4 or 5 8,936,274 
 Patients with inhibitors 7 
(inhibitor* or alloantibod* or immune toler* or 
autoantibod*).tw. 
2,648,102 
 Exclusion terms 
8 (conference abstract or conference review).pt. 2,946,970 
9 limit 8 to yr="1946-2014" 1,907,607 
10 exp Animals/ not exp humans/ 9,104,800 
 Combined  
11 9 or 10 10,832,433 
12 3 and 6 and 7 2,925 
13 12 not 11 2,200 
 Total 14 remove duplicates from 13 1,383 
MEDLINE, MEDLINE In-Process, MEDLINE Daily and MEDLINE Epub Ahead of 4 
Print (1946 to present); Embase (1974 to 23 March 2018). 5 
 6 
6XSSOHPHQWDO'DWD)LOHGRFWLISGIHWF
Supplementary Table 2. Search Terms for The Cochrane Library (Searched 1 
via the Wiley Online Platform) 2 
Term group # Searches Hits 
Patients with 
haemophilia 
1 [mh "hemophilia A"] or [mh "hemophilia B"]  340 
2 (hemophilia* or haemophilia*):ti,ab,kw  1,019 
3 #1 or #2  1,019 
Intervention 
4 (surgery* or surgic* or operat* or procedure* or 
dental):ti,ab,kw  
286,413 
5 [mh "surgical procedures, operative"]  122,148 
6 #4 or #5  334,058 
Patients with 
inhibitors 
7 (inhibitor* or alloantibod* or immune toler* or 
autoantibod*):ti,ab,kw  
76,222 
Total 
8 #3 and #6 and #7 in Cochrane Reviews (Reviews and 
Protocols), Other Reviews and Trials 
98 
The Cochrane Database of Systematic Reviews (CDSR): Issue 3 of 12, March 3 
2018; The Database of Abstracts of Reviews of Effects (DARE): Issue 2 of 4, 4 
April 2015; The Cochrane Central Register of Controlled Trials (CENTRAL): 5 
Issue 2 of 12, February 2018. 6 
 7 
Supplementary Table 3. Search Terms for Congress Proceedings 1 
Congress Link Search strategy Hits 
American Society of 
Hematology (ASH) 
Annual Meeting 
(2015, 2016, 2017) 
2015: 
http://www.bloodjournal.org/content/126
/23 
2016: 
http://www.bloodjournal.org/content/128
/22  
2017: 
http://www.bloodjournal.org/content/130
/Suppl_1 
 
The following terms were 
searched one by one for 
both years: 
x Hemophil 
x Haemophil 
2015: 34 
2016: 26 
2017: 10 
British Society for 
Haematology (BSH) 
Annual Scientific 
Meeting (2016, 2017) 
2016: Abstract book was in PDF form 
2017: Abstract book was in PDF form 
The following terms were 
searched one by one for 
both years: 
x Hemophil 
x Haemophil 
2016: 6 
2017: 7 
European Association 
for Haemophilia and 
Allied Disorders 
(EAHAD) Annual 
Congress (2016, 
2017) 
2016: Abstract book was in PDF form 
2017: Abstract book was in PDF form 
The following terms were 
searched one by one for 
both years: 
x Surg 
x Operat 
x Proced 
x Dental 
2016: 54 
2017: 53 
Haemophilia and 
thrombosis research 
society (HTRS) 
Scientific Symposium 
(2015, 2017) 
2015: Abstract book was in PDF form 
2017: Abstract book was in PDF form 
The following terms were 
searched one by one for 
both years: 
x Surg 
x Operat 
x Proced 
x Dental 
2015: 14  
2017: 20 
European 
Haemophilia 
Consortium (EHC) 
Annual Conference 
(2015, 2016) 
Abstract books for 2015 and 2016 were 
unavailable so were not searched   
European Hematology 
Association (EHA) 
Congress (2016, 
2017) 
2016: Abstract book was in PDF form 
2017: Abstract book was in PDF form 
The following terms were 
searched one by one for 
both years: 
x Hemophil 
x Haemophil 
2016: 27  
2017: 13 
International Society 
for Thrombosis and 
Haemostasis (ISTH) 
Congress (2016, 
2017) 
2016: Abstract book was in PDF form 
2017: Abstract book was in PDF form and 
the website was also searched 
(http://www.professionalabstracts.com/is
th2017/iplanner/#/grid) 
The following terms were 
searched one by one for 
both years: 
x Surg 
x Operat 
x Proced 
x Dental 
2016: 59  
2017: 100 
World Federation of 
Hemophilia (WFH) 
World Congress 
(2016) 
Abstract book was in PDF form 
The following terms were 
searched one by one: 
x Surg 
x Operat 
x Proced 
x Dental 
79 
 2 
Supplementary Table 4. Eligibility Criteria for the Systematic Review 1 
PICOS domain Inclusion criteria Exclusion criteria 
Population Haemophilia A patients with inhibitors at time 
of surgery 
Haemophilia B patients with inhibitors at time 
of surgery  
Patients with acquired haemophilia 
Haemophilia A patients without inhibitors (at 
time of surgery) 
Haemophilia B patients without inhibitors (at 
time of surgery) 
 
Intervention(s) Patients undergoing surgery (haemophilia-
related or unrelated procedures, including 
dental procedures) 
Patients not undergoing surgical procedures 
Comparator(s) Any or none No exclusion criteria 
Outcomes Details of perioperative management 
employed in the population of interest, 
including: 
x Monitoring of haemoglobin 
x Monitoring of haemostatic efficacy 
x Need to change dosing of haemostatic 
treatment or need for change in 
treatment 
x Use of thromboprophylaxis 
x Use of antifibrolytics 
x Laboratory monitoring of global 
haemostasis (ROTEM, TEG, thrombin 
generation assessment) 
x Duration of treatment 
Outcomes relating to the success of 
perioperative management, including: 
x Bleeding control 
x Wound healing outcomes 
x Survival 
x Re-operation/re-admission 
x Infection rates 
x Other management-related 
complications 
Studies not reporting outcomes related to 
monitoring or management of haemophilia 
patients for surgery 
Study design All study designs 
Any study presenting original data was eligible 
for inclusion 
Studies not presenting original data were 
excluded 
Other 
considerations 
Studies with abstracts or full-texts in the 
English language 
Only studies with human participants were 
included 
Studies not published in the English language 
Animal studies were excluded 
ROTEM: Rotational thromboelastometry; TEG: Thromboelastography 2 
Supplementary Table 5. Studies Excluded After Full Text Screening 1 
Study Reason for Exclusion 
Al-Salama ZT, Scott LJ. Lonoctocog Alfa: A Review in Haemophilia A. Drugs 2017;77:1677-1686.  Study design 
Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with 
hemophilia A or B with inhibitors: Results of the novoseven emergency-use program. Haemostasis 1998;28:93-98. Wrong population 
Balta A, Tornemo M, Radulovic V, et al. Monitoring of treatment with bypassing agents in patients with acquired and congenital haemophilia with 
inhibitors using ROTEM: A single-centre experience. Haematologica 2015;100:669-670. Wrong population 
Bayram I, Erbey F, Erdem S, et al. Recombinant factor VIIa and activated prothrombin-complex concentrate administration in the management of 
bleeding, coagulopathy and intractable coagulopathy in pediatric patients undergoing invasive medical procedures or surgery. UHOD - Uluslararasi 
Hematoloji-Onkoloji Dergisi 2009;19:205-212. 
Wrong population 
Bedoya M, Acord M, Srinivasan A, et al. Implantable venous access devices in boys with severe hemophilia: At a tertiary pediatric institution. 
Pediatric Radiology 2017;47:S86. Irrelevant intervention 
Berger K, Frey L, Spannagl M, et al. Health economic aspects of the use of blood and blood products. [German]. Bundesgesundheitsblatt, 
Gesundheitsforschung, Gesundheitsschutz 2006;49:64-72. Study design 
Berntorp E, Astermark J, Baghaei F, et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a 
systematic review as part of a Swedish health-technology assessment. Haemophilia 2012;18:158-65. Study design 
Biron-Andreani C, de Moerloose P, D'Oiron R, et al. Cancer detection and management in patients with haemophilia: A retrospective European 
multicentre study. Haemophilia 2013;20:78-82. 
Irrelevant intervention 
Birschmann I, Klamroth R, Eichler H, et al. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor 
VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Haemophilia 2013;19:679-685. Irrelevant intervention 
Blanchette VS, al-Musa A, Stain AM, et al. Central venous access catheters in children with haemophilia. Blood Coagulation & Fibrinolysis 1996;7 
Suppl 1:S39-44. Irrelevant intervention 
Boardman KP, English P. Fractures and dislocations in hemophilia. Clinical Orthopaedics and Related Research 1980;No. 148:221-232. Irrelevant intervention 
Bona RD, Weinstein RA, Weisman SJ, et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia. American Journal 
of Hematology 1989;32:8-13. 
Irrelevant intervention 
Borhany M, Abid M, Fatima N, et al. Hemophilia care in Pakistan. Blood Transfusion 2017;15 (Supplement 3):s493.  Irrelevant intervention 
Bulik O, Bulikova A, Smejkal P, et al. Preparation of patients with haemostasis disorder for dental surgery. [Czech]. Vnitrni Lekarstvi 2008;54:415-
420. Study design 
Caviglia H, Candela M, Landro ME, et al. Haemophilia pseudotumours in patients with inhibitors. Haemophilia 2015;21:681-685. Study design 
Colvin BT. Role of plasma-exchange in the management of patients with factor VIII inhibitors. La Ricerca in clinica e in laboratorio 1983;13:85-93. Study design 
Cooper HA, Gilchrist GS, Hoots WK, et al. Comparison of two doses of recombinant factor Vlla (rFVlla) for producing hemostasis during and after 
surgery in patients (PTS) with hemophilia A or B and inhibitors and PTS with acquired inhibitors. Blood 1997;90:600a.  Study design 
Study Reason for Exclusion 
Coppola A, Minno M, Tufano A, et al. Treatment for preventing bleeding in people with congenital bleeding disorders undergoing surgery: A 
systematic review of randomised controlled trials. Thrombosis research. Volume 134, 2014:S4-s5. Study design 
Coppola A, Windyga J, Tufano A, et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders 
undergoing surgery. The Cochrane database of systematic reviews 2015;2:CD009961. Study design 
Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia 
patients with inhibitors undergoing elective surgery. Blood 2010;116:5734-5737. 
Study design 
Dargaud Y, Pavlova A, Lacroix-Desmazes S, et al. Achievements, challenges and unmet needs for haemophilia patients with inhibitors. 
Haemophilia 2016;22:1-24. Study design 
Dekoven M, Wisniewski T, Petrilla A, et al. Patient/caregiver perceived benefits and barriers to elective orthopedic surgery (EOS) in patients with 
congenital hemophilia with inhibitors. Journal of Medical Economics 2012;15:305-312. Irrelevant intervention 
Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003;9:50-56. Irrelevant intervention 
Economou M, Teli A, Adremerina A, et al. Absence of thrombotic complications with the use of bypassing agents in young hemophilia patients with 
inhibitor presence. Haemophilia 2018;24 (Supplement 1):105.  
Irrelevant intervention 
Escobar M, Maahs J, Hellman E, et al. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United 
States: Perspectives and best practices derived from experienced treatment centres. Haemophilia 2012;18:971-981. Study design 
Furukawa S, Nogami K, Ogiwara K, et al. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the 
perioperative period using rotational thromboelastometry. Journal of Thrombosis and Haemostasis 2015;13:350. Duplicate 
Galstian GM, Spirin M, Zozulya N, et al. Providing hemostasis for long-term central venous access device (LTCVAD) placement in patients with 
factor VIII (fVIII) inhibitors. Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH 2017;130.  Irrelevant intervention 
Ghosh K, Shetty S, Jijina F, et al. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 
2004;10:58-62. 
Wrong population 
Givol N, Hirschhorn A, Lubetsky A, et al. Oral surgery-associated postoperative bleeding in haemophilia patients - a tertiary centre's two decade 
experience. Haemophilia 2015;21:234-240. 
Irrelevant intervention 
Goodnight Jr SH, Common HH, Lovrien EW. Factor VIII inhibitor following surgery for epidural hemorrhage in hemophilia: successful therapy with 
a concentrate containing factors II, VII, IX, and X. Journal of Pediatrics 1976;88:357-358. Wrong population 
Gozden HE, Ozkalemkas F, Ozkocaman V, et al. Evaluation of patients with hemophilia; Uludag University experience. Thrombosis Research 
2016;141:S37. Wrong population 
Haque Q, Feng X, Abuduaini Y. Intracranial haemorrhage in children with inherited bleeding disorders: A single center study in China. Hong Kong 
Journal of Paediatrics 2018;23(1):69.  Irrelevant intervention 
Haque Q, Li C, Abuduaini Y, et al. Intracranial hemorrhage in children with inherited bleeding disorders: A single center study in China. Blood. 
Conference: 59th Annual Meeting of the American Society of Hematology, ASH 2017;130.  
Duplicate 
Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. 
Thrombosis and Haemostasis 1997;78:1463-1467. Irrelevant intervention 
Hedner U. Factor VIIa in the treatment of haemophilia. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 
1990;1:307-317. Study design 
Study Reason for Exclusion 
Hirose J, Takedani H, Koibuchi T. The risk of elective orthopaedic surgery for haemophilia patients: Japanese single-centre experience. 
Haemophilia 2013;19:951-955. Irrelevant intervention 
Holmstrom M, Astermark J, Brodin E, et al. Swedish national registry for bleeding disorders-first report. Haemophilia 2018;24 (Supplement 1):101.
  Wrong population 
Hvid I, Rodriguez-Merchan EC. Orthopaedic surgery in haemophilic patients with inhibitors: An overview. Haemophilia 2002;8:288-291. Study design 
Jones ML, Wight J, Paisley S, et al. Control of bleeding in patients with haemophila A with inhibitors: A systematic review. Haemophilia 
2003;9:464-520. Study design 
Kenet G, Lubetsky A, Gitel S, et al. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment 
protocols with recombinant activated factor VII. Blood Coagulation and Fibrinolysis 2000;11:S35-S38. Wrong population 
Kleinschmidt S, Plinkert PK, Fuchs-Buder T, et al. [Haemostatic disorders in ENT patients.Part 2: Pathophysiology, diagnostics, clinical feature and 
therapy]. HNO 2003;51:251-266. Study design 
Klintman J, Berntorp E. Epidemiological aspects of inhibitor development in hemophilia and strategies of management. Expert Opinion on Orphan 
Drugs 2016;4:153-168. 
Study design 
Klukowska A, Laguna P, Rawicz M. Procedures for CV catheters insertion in children with congenital coagulation disorders. [Polish]. Medycyna 
wieku rozwojowego 2008;12:1126-1129. Irrelevant intervention 
Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally 
treated young children with severe haemophilia A: Results of an international clinical investigation. Thrombosis and Haemostasis 2005;93:457-
467. 
Wrong population 
Kulkarni R, Presley RJ, Lusher JM, et al. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease 
Control and Prevention Universal Data Collection System. Haemophilia 2017;23:207-214. Wrong population 
Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 
2005;11:2-4. Study design 
Liesner RJ, Abashidze M, Aleinikova O, et al. Immunogenicity, efficacy and safety of Nuwiq<sup></sup> (human-cl rhFVIII) in previously 
untreated patients with severe haemophilia A-Interim results from the NuProtect Study. Haemophilia 2017;16:16.  Irrelevant intervention 
Lim MY, Nielsen B, Ma A, et al. Clinical features and management of haemophilic pseudotumours: A single US centre experience over a 30-year 
period. Haemophilia 2013;20:e58-e62. Study design 
Lulla RR, Allen GA, Zakarija A, et al. Transplacental transfer of postpartum inhibitors to factor VIII. Haemophilia 2010;16:14-17. Wrong population 
Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe 
haemophilia A. Haemophilia 2003;9:38-49. Irrelevant intervention 
Makris M. Systematic review of the management of patients with haemophilia A and inhibitors. Blood Coagulation and Fibrinolysis 2004;15:S25-
S27. Study design 
McPherson J, Teague L, Lloyd J, et al. Experience with recombinant factor VIIa in Australia and New Zealand. Haemostasis 1996;26:109-117. Study design 
Mingot-Castellano ME, Perez-Montes R, Canaro M, et al. Successful treatment of bleeding in acquired hemophilia A with activated prothrombin 
complex concentrate in Spain. Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH 2017;130. Irrelevant intervention 
Study Reason for Exclusion 
Mortazavi SMJ, Najafi A, Toogeh G. Total joint replacement in haemophilia A patients with high titre of inhibitor using a new brand recombinant 
factor VIIa (Aryoseven<sup></sup>). Haemophilia 2016;22:e451-e453. Study design 
Negrier C, Ragni MV, Georgiev P, et al. Perioperative management in patients with hemophilia receiving fitusiran, an investigational rnai 
therapeutic targeting antithrombin for the treatment of hemophilia. Blood. Conference: 59th Annual Meeting of the American Society of 
Hematology, ASH 2017;130.  
Duplicate 
Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scandinavian Journal of 
Haematology 1976;16:369-382. 
Study design 
Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A 
review of the literature. Haemophilia 2008;14:233-241. Study design 
Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis 
from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005;11:100-106. 
Irrelevant intervention 
Park YS. Preferences between surgical or medical treatment in hemophilia patients with spontaneous epidural hematoma may vary. Haemophilia 
2018;24 (Supplement 1):133.  
Irrelevant intervention 
Pruthi RK, Mathew P, Valentino LA, et al. An open-label, randomized, parallel, multi-center trial comparing the safety and efficacy of rFVIIa when 
administered as IV bolus or IV continuous infusion to hemophilia patients with inhibitors during and after surgery. Blood 2004;104:3975. Irrelevant intervention 
Rodriguez-Merchan EC. Surgery in haemophilic patients with inhibitors. Haemophilia 2004;10 Suppl 2:1-2. Duplicate 
Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003;9:625-31. Duplicate 
Rudowski WJ. Major surgery in hemophilia. Annals of the Royal College of Surgeons of England 1981;63:111-117. Irrelevant intervention 
Salaj P, Louzil J, Geierova V, et al. Diagnosis and management of acquired haemophilia-single centre experience. Journal of Thrombosis and 
Haemostasis 2016;14:56. Irrelevant intervention 
Salcioglu Z, Sen HS, Tugcu D, et al. Congenital factor deficiencies: Twenty-five-year follow-up. Journal of Thrombosis and Haemostasis 
2015;13:358-359. 
Irrelevant intervention 
Salzmann G, Schramm W, Feifel G. The hemophiliac as a surgical patient. [German]. Munchener Medizinische Wochenschrift 1977;119:677-684. Wrong population 
Schoppmann A, Jaeger K, Berg R, et al. Review of the literature of FEIBA administration in patients with hemophilia B and inhibitors. Journal of 
Coagulation Disorders 2011;3:14-26. Study design 
Schulz, S. Inhibitor hemophilia in oral surgery. [German]. Zahn-, Mund-, und Kieferheilkunde mit Zentralblatt 1984;72:824-848.  Non-English language 
Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia 
A. New England Journal of Medicine 1990;323:1800-1805. Wrong population 
Seaman CD, Ragni MV. Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis. Blood Advances 
2017;1:1309-1311.  Study design 
See A, Sudirman SR, Huang XY. Spontaneous multilevel airway haemorrhage in acquired haemophilia A. European Archives of Oto-Rhino-
Laryngology 2016:1-4. Study design 
Serban M, Mihailov D, Pop L, et al. Development of inhibitors in haemophilia. Hamostaseologie 2011;31:S20-S23. Wrong population 
Study Reason for Exclusion 
Serban M, Ursu E, Cernat L, et al. Thrombin generation and whole blood viscoelastic assays in the monitoring of haemophilia with inhibitors. 
Haematologica 2016;101:407. Irrelevant intervention 
Sholzberg M, Phua C, Tsui H, et al. Heparin and protamine confound factor activity and inhibitor testing while on cardiopulmonary bypass. Journal 
of Thrombosis and Haemostasis 2015;13:807. Wrong population 
Shutov SA, Kovalenko AV, Soboleva OA, et al. [Surgical treatment of the complication of urolithiasis in patients with inhibitor form of hemophilia]. 
Khirurgiia 2017:104-107. 
Non-English language 
Smith MP, Giangrande P, Pollman H, et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active 
substance) in patients with haemophilia A. Haemophilia 2005;11:444-451. Wrong population 
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Supplementary Table 7. Quality Assessment of Interventional Studies Reporting Perioperative Laboratory Monitoring 1 
Study Did the 
trial 
address 
a 
clearly 
focused 
issue? 
Was the 
assignment 
of patients to 
treatments 
randomised? 
Were all of 
the patients 
who entered 
the trial 
properly 
accounted 
for at its 
conclusion? 
Were 
patients, 
health 
workers 
and study 
personnel 
'blind' to 
treatment? 
Were 
the 
groups 
similar 
at the 
start of 
the 
trial? 
Aside from 
the 
experimental 
intervention, 
were the 
groups 
treated 
equally? 
How large 
was the 
treatment 
effect? 
How 
precise 
was the 
estimate 
of the 
treatment 
effect? 
Can the 
results be 
applied in 
your 
context? (Or 
the local 
population?) 
Were all 
clinically 
important 
outcomes 
considered? 
Furukawa S 
et al. 
2015[20] 
Y N Y N N N - - Y N 
Gatti L et al. 
1984[13] 
Y N Y N - - - - N Y 
Ludlam A et 
al. 2003[10] 
Y N Y N - - - - Y Y 
Mancuso ME 
et al. 
2016[25] 
Y N Y N N N - - Y N 
Pruthi RK et 
al. 2007[19] 
Y Y Y N N N - - Y Y 
Santagostino 
E et al. 
2001[97] 
Y N Y N - - - - Unclear Y 
Scharrer I. 
1999[15] 
Y N Y N - - - - N N 
Shapiro AD 
et al. 
1998[73] 
Y Y Y Y Y Y - - Y Y 
Study Did the 
trial 
address 
a 
clearly 
focused 
issue? 
Was the 
assignment 
of patients to 
treatments 
randomised? 
Were all of 
the patients 
who entered 
the trial 
properly 
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conclusion? 
Were 
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health 
workers 
and study 
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trial? 
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experimental 
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applied in 
your 
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clinically 
important 
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considered? 
Smith MP et 
al. 2001[18] 
Y N Y N - - - - Y Y 
Y: Yes; N: No 1 
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Supplementary Table 8. Quality Assessment of Observational Studies Reporting Perioperative Laboratory Monitoring 1 
Study Was the cohort 
recruited in an 
acceptable 
way? 
Was the 
exposure 
accurately 
measured to 
minimise bias? 
Was the 
outcome 
accurately 
measured to 
minimise bias? 
Have the authors 
identified all 
important 
confounding 
factors? 
Have the authors 
taken account of the 
confounding factors in 
the design and/or 
analysis? 
Was the 
follow-up of 
patients 
complete? 
How precise (for 
example, in 
terms of CI and 
p values) are the 
results? 
Balkan C et al. 
2010[12] 
Y - Y - - Y - 
Danielson H et 
al. 2017[24] 
Y - Unclear - - Y - 
Habermann B 
et al. 2004[23] 
Unclear - N - - Y - 
Holmstrom M 
et al. 2012[22] 
Unclear - Y - - Y - 
Ingerslev J et 
al. 1996[49] 
Unclear - N - - Y - 
Kraut EH et al. 
2007[14] 
N - N - - Y - 
Lauroua P et 
al. 2009[54] 
Y - Y - - Y - 
Mauser-
Bunschoten EP 
et al. 1998[16] 
Unclear - N - - Y - 
Mauser-
Bunschoten EP 
et al. 2002[17] 
Y - N - - Y - 
Negrier C et al. 
2013[93] 
Y - Y - - Y - 
Study Was the cohort 
recruited in an 
acceptable 
way? 
Was the 
exposure 
accurately 
measured to 
minimise bias? 
Was the 
outcome 
accurately 
measured to 
minimise bias? 
Have the authors 
identified all 
important 
confounding 
factors? 
Have the authors 
taken account of the 
confounding factors in 
the design and/or 
analysis? 
Was the 
follow-up of 
patients 
complete? 
How precise (for 
example, in 
terms of CI and 
p values) are the 
results? 
Quintana-
Molina M et al. 
2004[65] 
Y - Y - - Y - 
Serban M et 
al. 2014[21] 
Y - Y - - Y Unclear 
Smith OP et al. 
2002[75] 
Y - Unclear - - Unclear - 
Tjonnfjord GE. 
2004, 2006 
[100, 101] 
Y - Unclear - - Y - 
Y: Yes; N: No 1 
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